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1.  INTRODUCTION 
 
 
 
(Raymond C.Rowe., 2003) 
 
Cyclodextrins are cyclic oligosaccharides containing at least six D-(+)-  
glucopyranose   units   attached   by   α   (1Æ4)   glucoside   bonds.   The   three   natural 
cyclodextrins, α, β, and γ differ in their ring size and solubility. They contain 6, 7 or 8 
glucose units, respectively. 
 
 
Cyclodextrins occur as white, practically odourless, fine crystalline powders, 
having a slightly taste. Some cyclodextrins derivatives occur as amorphous powders. 
Cyclodextrins were discovered approximately 100 years ago with the foundation of 
cyclodextrin chemistry being laid down in the first half of this century. In the beginning, 
only small amounts of relatively impure cyclodextrins could be generated and high 
production costs prevented their industrial usage. Recent bio-technological advancements 
have resulted in drastic improvements in the efficiency of manufacture of cyclodextrins, 
lowering the cost of these materials and making highly purified cyclodextrins and 
cyclodextrin derivatives available. 
 
Cyclodextrins are used to increase the solubility of water insoluble drugs, through 
inclusion  complexation.  Natural  cyclodextrins  have  been  used  extensively  for  this 
purpose. However, they are characterized by relatively low solubility in water, which 
limits their application. Hence, chemically modified cyclodextrins are gaining 
considerable interest to improve the physicochemical properties of cyclodextrins. 
Cyclodextrins are known to form an inclusion complex with many drugs of appropriate 
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molecular size and polarity in hydrophobic drug molecules. The resulting complex 
generally  leads  to  an  improvement  in  some  of  the  properties  of  drugs  in  terms  of 
solubility, bioavailability and tolerability. 
 
Poorly water soluble drugs are generally associated with slow drug absorption 
leading eventually to inadequate and variable bioavailability. 
 
Cyclodextrins are ‘bucket like’ or ‘cone like’ toroid molecules, with a rigid 
structure and central cavity, the size of which varies according to the cyclodextrin type. 
The internal surface of the cavity is hydrophobic and the outside of the torus is 
hydrophilic; this is due to arrangement of hydroxyl groups within the molecule. This 
arrangement permits the cyclodextrin to accommodate a guest molecule within the cavity, 
forming an inclusion complex. 
 
The interaction of guest molecules with cyclodextrins may induce useful 
modifications of the chemical and physical properties of guest molecules, which may 
lead to improve stability, solubility in aqueous medium and bioavailability. Poorly water 
soluble drugs therefore can be orally administered in the complex form by taking 
advantage of the well established low toxicity of the cyclodextrins by the oral route. β- 
Cyclodextrin appears to be the most useful complexing agent because of its unique cavity 
size, and ease with which it can be obtained on the industrial scale leading to reasonably 
cheaper price of the compound. Pharmaceutical applications of cyclodextrins as additive 
and drug complexing agents have been rapidly growing.  
 
The behavior of the drug in the body involves the fate of the drug during it’s 
transmit as well as its fate while in the biophase. The drug potentially interacts with a 
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variety of substances leading to undesired drug loss as loss desired drug of absorption. In 
every instance the degree of this loss or absorption is a function of the drug and the type 
of the dosage form. 
 
1.1. Biopharmaceutics and Pharmacokinetics: 
 
 
(Brahmankar D.M and Sunil B. Jaiswal., 2009) 
 
 
Biopharmaceutics is the study of physiologic and pharmaceutical factors 
influencing drug release and absorption from dosage forms. The optimal delivery of the 
active moiety to the site of action depends on an understanding of specific interaction 
between formulation variables and biological variables. Absorption is defined as the 
amount of drug that reaches the general circulation in unchanged form from the site of 
administration. 
 
The  drug  efficacy  can  be  severely  limited  by  poor  aqueous  solubility.  An 
insoluble or sparingly soluble drug, if administered the rate of absorption and extent of 
bioavailability is controlled by dissolution rate in gastrointestinal fluid. The therapeutic 
effectiveness of a drug whose absorption is dissolution rate limited is hampered by its 
poor dissolution in an aqueous medium. The absorption of solid drugs administered 
orally can be depicted by the following chart.  
 
Solid drugs            Kd                   Drug solution             Ka                       Drug in systemic 
in GI fluids            Dissolution           in GI fluids              Absorption                         circulation 
where  Kd   and  Ka    are  the  rate  constants  for  dissolution  and  absorption  process 
respectively. 
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1.2. Methods for Enhancement of Bioavailability: 
 
 
(Brahmankar D.M and Sunil B. Jaiswal., 2009) 
 
 
As  far  as  the  definition  of  bioavailability  is  concerned,  a  drug  with  poor 
bioavailability is the one with 
 
1.   Poor aqueous solubility and / or slow dissolution rate in the biological fluids. 
 
 
2.   Poor stability of the dissolved drug at the physiologic pH.  
 
 
3.   Inadequate   partition   coefficient   and   thus   poor   permeation   through   the 
biomembrane. 
 
4.   Extensive presystemic metabolism. 
 
 
The three major approaches in overcoming the bioavailability problems due to 
such causes are: 
 
a. The Pharmaceutic Approach which involves modification of formulation, 
manufacturing process or the physicochemical properties of the drug without 
changing the chemical structure. 
 
b.   The  pharmacokinetic  approach  in  which  the  pharmacokinetics  of  the  drug  is 
altered by modifying its chemical structure. 
 
c.   The Biologic approach whereby the route of drug administration may be changed 
such as changing from oral to parenteral route. 
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The second approach of chemical structure modification has a number of 
drawbacks of being very expensive and time consuming, requires repetition of clinical 
studies and long time for regulatory approval. Moreover, the new chemical entity may 
suffer from another pharmacokinetic disorder or bear the risk of precipitating adverse 
effects. Only the pharmacokinetic approach will be dealt herewith.  
 
The attempts, whether optimizing the formulation, manufacturing process or 
physicochemical properties of the drug, are mainly aimed at enhancement of dissolution 
rate as it is the major rate limiting step in the absorption of most drugs. There are several 
ways in which the dissolution rate of a drug can be enhanced. Some of the widely used 
methods, most of which are aimed at increasing the effective surface area of the dugs will 
be discussed briefly. 
 
1.2.1. Techniques of Solubility Enhancement:  
 
 
(Mohanachandran P.S et al., 2010; Brahmankar D.M and Sunil B. Jaiswal., 2009) 
 
 
There are various techniques available to improve the solubility of poorly soluble 
drugs. Some of the approaches to improve the solubility are, 
a) Physical Modifications: 
Particle size reduction: 
•   Micronization 
 
 
•   Nanosuspension 
 
 
•   Sonocrystalisation 
 
 
•   Supercritical fluid process 
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Modification of the crystal habit: 
 
 
•   Polymorphs 
 
 
•   Pseudopolymorphs 
 
 
Drug dispersion in carriers: 
 
 
•   Eutectic mixtures 
 
 
•   Solid dispersions 
 
 
•   Solid solutions 
 
 
Complexation: 
 
 
•   Use of complexing agents 
 
 
Solubilization by surfactants: 
 
 
•   Microemulsion 
 
 
•   Self microemulsifying drug delivery systems 
b) Chemical Modifications: 
Physical Modifications: 
 
Particle size reduction: Particle size reduction can be achieved by micronisation and 
nanosuspension.   Each technique utilizes different equipments for reduction of the 
particle size. 
Micronization: The solubility of drug is often intrinsically related to drug particle 
size. By  reducing  the  particle  size,  the  increased  surface  area  improves  the 
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dissolution properties of the drug.  Conventional methods of particle size reduction, 
such as communication and spray drying, rely upon mechanical stress to disaggregate 
the active compound. 
Nanosuspension:  Nanosuspensions  are  sub-micron  colloidal  dispersion  of  pure 
particles of drug, which are stabilized by surfactants.   The advantages offered by 
nanosuspension is increased dissolution rate is due to larger surface are exposed, 
while absence of Ostwald ripening is due to the uniform and narrow particle size 
range obtained, which eliminates the concentration gradient factor. 
Sonocrystallisation:  Recrystallization  of  poorly  soluble  materials  using  liquid 
solvents and antisolvents has also been employed successfully to reduce particle size. 
The novel approach for particle size reduction on the basis of crystallization by using 
ultrasound  is  Sonocrystallisation.     Sonocrystallisation  utilizes  ultrasound  power 
characterized by a frequency range of 20-100 kHz for inducing crystallization.  It’s 
not only enhances the nucleation rate but also an effective means of size reduction 
and  controlling  size  distribution  of  the  active  pharmaceutical  ingredients.    Most 
applications use ultrasound in the range 20 kHz-5 MHz. 
Modification of the crystal habit: Polymorphism is the ability of an element or 
compound to crystallize in more than one crystalline form.  Different polymorphs of 
drugs are chemically identical, but they exhibit different physicochemical properties 
including solubility, melting point, density, texture and stability.  Broadly polymorphs 
can  be  classified  as  enantiotropes  and  monotropes  based  on  thermodynamic 
properties. 
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In the case of an enantiotropic system, one polymorphs form can change 
reversibly into another at a definite transition temperature below the melting point, 
while no reversible transition is possible for monotropes.   Once the drug has been 
characterized  under  one  of this  category,  further  study involves the detection of 
metastable form of crystal.  Metastable forms are associated with higher energy and 
thus higher solubility. 
 
Drug dispersion in carriers :  The solid dispersion approach to reduce particle size 
and  therefore  increase  the  dissolution  rate  and  abso rption  of  drugs  was  first 
recognized in 1961.  The term “solid dispersions” refers to the dispersion of one or 
more active ingredients in an inert carrier in a solid state, frequently prepared by the 
melting method, solvent method, or fusion solvent- method. Novel additional 
preparation techniques have included rapid precipitation by freeze drying and using 
supercritical fluids and spray drying, often in the presence of amorphous hydrophilic 
polymers and also using methods such as melt extrusion. 
 
Complexation: Complexation is the association between two or more molecules to 
form a nonbonded entity with a well defined stoichiometry.  Complexation relies on 
relatively weak forces such as London forces, hydrogen bonding and hydrophobic 
interactions. 
 
Staching complexation: Staching complexes are formed by the overlap of the planar 
regions of aromatic molecules, Nonpolar moieties tend to be squeezed out of water by 
the strong hydrogen bonding interactions of water.  This causes some molecules to 
minimize the contact with water by aggregation of their hydrocarbon moieties.  This 
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aggregation is favored by large planar nonpolar regions in the molecule.   Stached 
complexes can by homogeneous or mixed.  The former is known as self association 
and latter as complexation. 
 
Inclusion complexation: Inclusion complexes are formed by the insertion of the 
nonpolar molecule or the nonpolar region of one molecule (known as guest) into the 
cavity  of  another  molecule  or  group  of molecules  (known  as  host).    The  major 
structural requirement for inclusion complexation is a snug fit of the guest into the 
cavity of host molecule.  The cavity of host must be large enough to accommodate the 
guest and small enough to eliminate water, so that the total contact between the water 
and the nonpolar regions of the host and the guest is reduced.   Three naturally 
occurring CDs are α-Cyclodextrin, β -Cyclodextrin, and γ – Cyclodextrin.   The 
complexation with cyclodextrins is used for enhancement of solubility.  Cyclodextrin 
inclusion is a molecular phenomenon in which usually only one guest molecule 
interacts with the cavity of a cyclodextrin molecule to become entrapped and form a 
stable association.   The internal surface of cavity is hydrophobic and external is 
hydrophilic; this is due to the arrangement of hydroxyl group within the molecule. 
The kinetics of cyclodextrin inclusion complexation has been usually analyzed in 
terms of a one – step reaction or a consecutive two – step reaction involving 
intracomplex structural transformation as a second step. Cyclodextrins is to enhance 
aqueous solubility of drugs through inclusion complexation. It was found that 
cyclodextrins increased the paclitaxel solubility by 950 fold, complex formation of 
rofecoxib, celecoxib, clofibrate, melarsoprol, taxol, cyclosporine A etc., with 
cyclodextrins improves the solutility of particular drugs. 
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Approaches for Making Inclusion Complexes: 
 
 
Physical blending method: A solid physical mixture of drug and CDs are prepared 
simply  by  mechanical  trituration.    In  laboratory  scale  CDs  and  drug  are  mixed 
together thoroughly by trituration in a mortar and passes through appropriate sieve to 
get the desired particle size in the final product. 
 
Kneading method: This method is based on impregnating the CDs with little amount 
of water or hydroalcoholic solutions to converted into a paste.  The drug is then added 
to the above paste and kneaded for a specified time.   The kneaded mixture is then 
dried and passed through sieve if required.  
 
Co – precipitation technique: This method involves the co – precipitation of drug 
and CDs in a complex.   In this method, required amount of drug is added to the 
solution of CDs.  The system is kept under magnetic agitation with controlled process 
parameters and the content is protected from the light.   The formed precipitate is 
separated by vacuum filtration and dried at room temperature in order to avoid the 
loss of the structure water from the inclusion complex. 
 
Solution / solvent evaporation method: This method involves dissolving of the drug 
and CDs separately in to two mutually miscible solvents, mixing of both solutions to 
get molecular dispersion of drug and complexing agents and finally evaporating the 
solvent under vacuum to obtain solid powdered inclusion compound.  Generally, the 
aqueous solution of CDs is simply added to the alcoholic solution of drugs.   The 
resulting mixture is stirred for 24 hours and evaporated under vacuum at 45° C.  The 
dried mass was pulverized and passed through a 60 – mesh sieve.   This method is 
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quite simple and economic both on laboratory and large scale production and is 
considered alternative to the spray drying technique. 
 
Neutralization precipitation method: This method is based on the precipitation of 
inclusion compounds by neutralization technique and consists of dissolving the drug 
in alkaline solutions like sodium / ammonium hydroxide and mixing with an aqueous 
solution of CDs.   The  resultant  clear  solution  is  then  neutralized  under  agitation 
using HCI solution till reaching the equivalence point. A white precipitate is being 
formed at this moment, corresponding to the formation of the inclusion compound. 
This precipitate is filtered and dried. 
 
Milling / Co – grinding technique: A solid binary inclusion compounds can be 
prepared by grinding and milling of the drug and CDs with the help of mechanical 
devices.  Drug and CDs are mixed intimately and the physical mixture is introduced 
in an oscillatory mill and grinded for suitable time. Alternatively, the ball milling 
process can also be utilized for preparation of the drug – CD binary system.  The ball 
mill  containing  balls  of  varied  size  is  operated  at  a  specified  speed  for  a 
predetermined time, and then it is unloaded, sieved through a 60 – mesh sieve.  This 
technique is superior to other approaches from economic as well as environmental 
stand point in that unlike similar methods it does not require any toxic organic 
solvents.   This method differs from the physical mixture method where simple 
blending is sufficient and in co-grinding it requires to achieve extensive combined 
attrition and impact effect on powder blend. 
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Atomization / spray drying method: Spray – drying is a common technique used in 
pharmaceuticals to produce a dry powder from a liquid phase.  Another application is 
its use as a preservation method, increasing the storage stability due to the water 
elimination.  This method represents one of the most employed methods to produce 
the inclusion complex starting from a solution.  The mixture pass to a fast elimination 
system propitiate solvent and shows a high efficiency in forming complex.  Besides, 
the product obtained by this method yield the particles in the controlled manner 
which in turn improves the dissolution rate of drug in complex form. 
 
Lyophilization / Freeze drying technique: In order to get a porous, amorphous 
powder with high degree of interaction between drug & CD, lyophilization / freeze 
drying technique is considered as a suitable.   In this technique, the solvent system 
from the solution is eliminated through a primary freezing and subsequent drying of 
the  solution  containing  both  drug  &  CD  at  reduced  pressure.     Thermolabile 
substances can be successfully made into complex form by this method.   The 
limitations of the technique are long time process and yield poor flowing powdered 
product.  Lyophilization /freeze drying technique are considered as an alternative to 
solvent evaporation and involve molecular mixing of drug and carrier in a common 
solvent. 
 
Microwave irradiation method: This technique involves the microwave irradiation 
reaction between drug and complexing agent using a microwave oven. The drug and 
CD in definite molar ratio are dissolved in a mixture of water and organic solvent in a 
specified proportion into a round bottom flask. The mixture is reacted for short time 
of about one to two minutes at 60° C in the microwave oven. After the reaction 
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completes, adequate amount of solvent mixture is added to the above reaction mixture 
to remove the residual, uncomplexed free drug and CD.  The precipitate so obtained 
is separated using whatman filter paper, and dried in vacuum oven at 40° C from 
48 hrs. 
 
 
Supercritical antisolvent technique: In this technique, carbon dioxide is used as 
anti- solvent for the solute but as a solvent with respect to the organic solvent. The 
use of supercritical carbon dioxide is advantageous as its low critical temperature and 
pressure makes it attractive for processing heat – labile pharmaceuticals. It is also non 
– toxic, nonflammable, inexpensive and is much easier to remove from the polymeric 
materials when the process is complete, even through small amount of carbon dioxide 
remains trapped inside the polymer, it poses no danger to the consumer.  Supercritical 
particle generation processes are new and efficient route for improving bioavailability 
of pharmaceutically active compounds.  In addition, supercritical fluid processes were 
recently  proposed  as  a  new  alternative  method  for  the  preparation  of  drug 
cyclodextrin complexes.   Supercritical carbon dioxide is suggested as a new 
complexation medium due to its properties of improved mass transfer and increased 
solvating power.   This method constitutes one of the most innovators methods to 
prepare the inclusion complex of drug with CD in solid state. This is a non – toxic 
method as it is not utilizing any organic solvent, fast process, maintenance cost is low 
with promising results, but it requires a quite high initial cost. 
 
In this technique, first, drug and CD are dissolved in a good solvent then the 
solution is fed into a pressure vessel under supercritical conditions, through a nozzle 
(i.e. sprayed into supercritical fluid anti – solvent).  When the solution is sprayed into 
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supercritical fluid anti – solvent, the anti – solvent rapidly diffuses into that liquid 
solvent as the carrier liquid solvent counter diffuses into the anti– solvent.  Because 
of the supercritical fluid expanded solvent has lower solvent power than the pure 
solvent, the mixture becomes supersaturated resulting in the precipitation of the solute 
and the solvent is carried away with the supercritical fluid flow. 
 
Solubilization by surfactants: 
 
 
Surfactants are molecules with distinct polar and nonpolar regions.   Most 
surfactants consist of a hydrocarbon segment connected to a polar group.  The polar 
group can be anionic, cationic, zwitterionic or nonionic. When small apolar molecules 
are added they can accumulate in the hydrophobic core of the micelles. 
 
This process of solubilization is very important in industrial and biological 
processes.  The presence of surfactants may lower the surface tension and increase the 
solubility of the drug within an organic solvent. 
 
Micro emulsions: The term microemulsion was first used by Jack H. Shulman in 
 
1959. A microemulsion is a four component system composed of external phase, 
internal phase, surfactant and cosurfactant. The addition of surfactant, which is 
predominately soluble in the internal phase unlike the cosurfactant, results in the 
formation of an optically clear, isotropic, thermodynamically stable emulsion.  It is 
termed as microemulsion because of the internal or dispersed phase is <0.1 µ droplet 
diameter.  The formation of microemulsion is spontaneous and does not involve the 
input of external energy as in case of coarse emulsions.   The surfactant and the 
cosurfactant  alternate  each  other  and  form  a  mixed  film  at  the  interface,  which 
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contributes to the stability of the microemulsions.  Non – ionic surfactants, such as 
Tweens and Labrafil with high hyrophile – lipophile balances are often used to ensure 
immediate formation of oil – in – water droplets during production.  Advantages of 
microemulsion  over  coarse  emulsion  include  its  ease  of  preparation  due  to 
spontaneous formation, thermodynamic stability, transparent and elegant appearance, 
increased drug loading, enhanced penetration through the biological membranes, 
increased bioavailability, and less inter-and intra – individual variability in drug 
pharmacokinetics. 
 
Chemical Modifications: 
 
 
For organic solutes that are ionizable, changing the pH of the system may be 
simplest and most effective means of increasing aqueous solubility.  Under the proper 
conditions, the solubility of an ionizable drug can increase exponentially by adjusting 
the pH of the solution. A drug that can be efficiently solubilized by pH control should 
be either weak acid with a low pKa or a weak base with a high pKa.  Similar to the 
lack of effect of heat on the solubility of non – polar substances, there is little effect 
of pH on nonionizable substances. Nonionizable, hydrophobic substances can have 
improved solubility by changing the dielectric constant of the solvent by the use of 
co-solvents rather than the pH of the solvent. The use of salt forms is a well known 
technique to enhanced dissolution profiles. Salt formation is the most common and 
effective method of increasing solubility and dissolution rates of acidic and basic 
drugs.   An alkaloid base is, generally, slightly soluble in water, but if the pH of 
medium is reduced by addition of acid, and the solubility of the base is increased as 
the pH continues to be reduced.  The reason for this increase in solubility is that the 
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base is converted to a salt, which is relatively soluble in water.   The solubility of 
slightly soluble acid increased as the pH is increased by addition of alkali, the reason 
being that a salt is formed. 
 
1.3. Monomolecular Inclusion Complexes: 
 
(Martin’s., 2006) 
 
Monomolecular inclusion compounds involve the entrapment of a single guest 
molecule in the cavity of one host molecule.   Most of the host molecules are 
cyclodextrins.  Cyclodextrins are cyclic oligo-saccharides containing a minimum of 
six D-(+) glucopyranose units attached by alpha-1,4 linkage. Three types of 
cyclodextrins namely α, β, γ consist of 6, 7 and 8 units of glucose, respectively. 
Alpha cyclodextrin has the smallest cavity (internal diameter almost 5 A).  Beta and 
gamma cyclodextrins have larger internal diameter (6 and 8 A. respectively) and are 
useful for pharmaceutical technology. 
 
The   structures   of   cyclodextrins   assume   a   truncated   cone   and   can 
accommodate a wide varity of compounds.   The interior of the cavity is relatively 
hydrophobic, whereas the entrance of the cavity is hydrophilic in nature.  
 
Applications : These types of complexes are extensively studied for their possible 
uses in the design of dosage forms. 
 
Enhanced solubility: The solubility of retinonic acid (0.5 mg/litre) is increased to 
 
160 mg/litre by complexation with β -cyclodextrin. 
 
 
Enhanced dissolution: The dissolution rate of drugs such as famotidine and 
tolbutamide is enhanced by complexation with β -cyclodextrin. 
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Enhanced stability: The stability of drugs such as aspirin, benzocaine, ephedrine and 
testosterone is improved when complexed with β cyclodextrin.   The inclusion 
complexes protect the drugs by preventing the exposure of the functional groups to 
the exterior of the environment. 
 
Sustained release: Ethylated β -cyclodextrin retards the release of drugs such as 
diltiazem and isosorbide dinitrate, when complexed.   The drug releases slowly for 
prolonged periods and provides sustained effect.  
 
1.4. Cyclodextrin: 
 
(Loftsson T. et al., 1996;  Gerold Mosher et al., 2007; Szejtli J.,1990)  
 
Cyclodextrin or cycloamylases which have recently been recognized as useful 
pharmaceutical excipient and comprise a family of cyclic oligosaccharides produced 
from starch by enzymatic degradation. The enzyme cyclodextrin-glucosyl transferase 
produced by Bacillus macerans acts on partially hydrolyzed starch and produces a 
mixture of cyclic and acyclic dextrins from which cyclodextrin are isolated.  
 
The β-cyclodextrin appears to be the most useful complexing agent because of 
its unique cavity size and ease with which it can be obtained on industrial scale. β- 
Cyclodextrin displays a water solubility of 1.8 g/100 ml. Recently derivatives of β- 
cyclodextrin have been received considerable attention because of their higher water 
solubility (>50 g/100 ml). Partial methylation of some of the hydroxyl (OH) groups in 
cyclodextrin reduces the inter-molecular hydrogen bonding, leaving some hydroxyl 
groups free to interact with water, thus increasing the aqueous solubility of 
cyclodextrins. They belong to methylated β-cyclodextrins (dimethyl β-CD and 
trimethyl  β-CD).  Hydroxy  alkylation  of  the  hydroxyl  groups  of  the  cyclodextrin 
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produced hydroxy alkylated β-cyclodextrins (2 hydroxy ethyl β-CD, 2 hydroxypropyl 
β-CD). This modification results in greater solubility, of hydroxypropyl β- 
cyclodextrin and its complexes compared to β-cyclodextrin. The hydroxy groups and 
the hydroxypropyl groups are on the exterior of the molecule and interact with water 
to provide the increased aqueous solubility of the hydroxypropyl β-cyclodextrin. 
 
 
 
 
Fig. 1.1: Structure of cyclodextrins 
 
 
The most stable three-dimensional structure of cyclodextrin is a toroid with 
the larger and smaller openings presenting hydroxyl groups to the external 
environment and mostly hydrophobic functionality lining the interior and the cavity.  
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Fig. 1.2: Molecular structure of β-cyclodextrins 
 
 
It  is  the  unique  configuration  that  gives  cyclodextrins  their  interesting 
properties and creates the thermodynamic driving force needed to form host guest 
complexes with a polar molecules and functional groups. 
 
1.4.1.   Chemistry of Cyclodextrin: 
 
 
(Raymond C.Rowe., 2003) 
 
 
Cyclodextrin are cyclic, non-reducing, water-soluble oligosaccharides. Three 
different forms of cyclodextrin known are α, β and γ. Cyclodextrins are also called 
Schardinger dextrins, cycloglucans or cycloamylases are α-1, 4 linked cyclic 
oligosaccharides obtained from enzymatic conversion of starch. The parent or natural 
cyclodextrins contain 6, 7 or 8 glucopyranose units.  
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Table 1.1: Characteristics of cyclodextrins 
 
 
 α β γ 
No. of glucose units 6 7 8 
Molecular weight 972 1135 1297 
Cavity diameter 4.7 – 5.3 6.0 – 6.5 7.5 – 8.3 
Water solubility (g/100 ml)  14.50 1.85 23.2 
Content (dry basis) >98 % >98 % >98 % 
Specific rotation in aqueous 
 
solution (α) 
D, 20  
 
 
+ 147 to +150° 
 
 
+160 to +164° 
 
 
+174 to +180° 
Water <10 % <14 % <11 % 
Heavy metals <5 ppm <5 ppm <5 ppm 
Cavity height (A°) 7.9 7.9 7.9 
Cavity volume (A°)³ 174 262 427 
 
 
In addition, all three cyclodextrins exhibit good flow properties and handling 
characteristics and are: 
 
• Thermally stable (<200° C) 
 
 
• Using stable alkaline solution (pH < 14).  
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• Stable in acidic solution (pp>3) 
 
 
• Biocompatible. 
 
 
1.4.2.   Method of Manufacture: 
 
 
Cyclodextrins are manufactured by the enzymatic degradation of starch using 
specialized  bacteria  (Bacillus  macerans).  The  insoluble  β-CD  organic  solvent 
complex is separated from the non-cyclic starch, and the organic solvent removed in 
vacuole so that less than 1 ppm of solvent remains in the β-CD. The cyclodextrin is 
then carbon treated and crystallized from water, dried and collected. 
 
Hydroxyethyl-β-CD is made by reacting β-CD with ethylene oxide, while 
hydroxypropyl-β-CD is made by reacting with propylene oxide.  
 
1.4.3.   Complexation of Cyclodextrins: 
 
(Martin’s., 2006) 
 
The ability to form inclusion compounds in aqueous solution is due to the 
typical arrangement of glucose units in aqueous solutions. Cyclodextrins form 
complexes with many drugs through a process in which the water molecules located 
in  the  central  cavity  are  replaced  by  either  the  whole  drug  molecule  or  more 
frequently by some lipophilic portion of the drug structure.  
 
The interior of the cyclodextrin cavity is relatively hydrophobic because of the 
presence of the skeletal carbons and ethereal oxygen, which comprise the cavity, 
whereas the cavity entrances are hydrophilic owing to the presence of the primary and 
secondary hydroxyl groups. As the water molecules located inside the cavity cannot 
satisfy their hydrogen bonding potential, they are having high enthalpy than bulk 
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water molecules located in the solution. Water inside the cavity tends to be squeezed 
out and to be replaced by more hydrophobic species. Thus, molecules of appropriate 
size and stereochemistry can be included in the cyclodextrin by hydrophobic 
interactions. 
 
Water is preferred solvent for complexation. The guest or proton of the which 
complexes with the cavity of cyclodextrin as a non-polar (hydrophobic) and prefers 
the non-polar environment of the cavity of cyclodextrin rather than polar aqueous 
environment as a result water provides a driving force for complexation reaction in 
addition to dissolving the guest and cyclodextrin. 
 
 
 
 
Fig. 1.3: Complexation of cyclodextrin 
 
 
The above figure provides a schematic representation of the equilibrium 
involved in forming an inclusion complex between cyclodextrin and toluene in the 
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presence of a small amount of water. In general, there are four energetically favorable 
interactions that help shift the equilibrium to right: 
 
• The displacement of polar water molecules from the a polar cyclodextrin 
cavity. 
 
• The  increased  number  of  hydrogen  bonds  formed  as  the  displaced  water 
returns to the larger pool. 
 
•  A reduction of the repulsive interactions between the hydrophobic guest and 
the aqueous environment. 
 
• An increase in the hydrophobic interactions as the guest inserts itself into the a 
polar cyclodextrin cavity. 
 
While this initial equilibrium to form the complex is very rapid (often within 
minutes), the final equilibrium can take much longer to reach. Once inside the 
cyclodextrin cavity, the guest molecule makes conformational adjustments to take 
maximum advantage of the weak Vander Waals’ forces that exist.  
 
1.5.   Preparation of Complexes: 
 
(Sanoferjan A.M et al., 2000; Chowdary K.P.R et al., 2000) 
 
Cyclodextrin complexes are prepared by the following methods: 
 
a)  Kneading method 
 
b)  Common solvent method 
c)  Physical mixture 
d)  Co-precipitate method 
Inclusion Complexes of Aceclofenac Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 24 
 
 
 
 
 
a)  Kneading method: 
 
 
β-Cyclodextrin was taken in a glass mortar and little water was added and 
mixed to obtain a homogenous paste.  Drug was then added slowly while grinding. 
The mixture was ground for 1 h during this process appropriate quantity of water was 
added to maintain suitable consistency.  The paste was dried in an oven at 40° C for 
48 hr.  The dried complex was taken for study. 
 
 
b)  Common solvent method: 
 
 
Drug and β-Cyclodextrin were dissolved in 25 % ammonia and the solvent 
was allowed to evaporate overnight at room temperature.  The complex so prepared 
was pulverized and sifted through sieve no.80.  
 
c)  Physical mixture: 
 
 
Previously weighted drug and Cyclodextrin mixture was blended in glass mortar 
for about an hour and passed through sieve no.85 to get physical mixture and stored 
in desiccator over fused calcium chloride. 
d)  Co-precipitate Method: 
 
 
Drug and cyclodextrin in different molar ratio are dissolved in different solvent. 
The solution of the drug is incorporated into solution of cyclodextrin drop wise with 
continuous stirring at room temperature for 1 hour and then slowly evaporated on a 
boiling water bath. The inclusion complex precipitated as a crystalline powder, which 
is then pulverized, sieved and stored in a desiccator till free from any traces of the 
organic solvent. 
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1.6. Phase Solubility Technique:                             (Higuchi T. and Connors K.A., 1965) 
 
“T. Higuchi and K.A. Connors” developed the phase solubility technique. It is 
based on research related to how complexes of different complexing agents such as 
cyclodextrin, caffeine, polyvinyl pyrrolidone and some aromatic acids affect the 
aqueous solubility of drug. 
 
1.6.1. Phase Solubility Diagrams: 
 
 
Phase solubility diagrams are plots of drug solubility versus cyclodextrin 
concentration. The stoichiometry of drug/cyclodextrin complexes and the numerical 
values of their stability constants are frequently obtained from phase solubility 
diagrams. 
 
The physicochemical properties of free drug molecules are different from 
those bound to the cyclodextrin molecules. Likewise, the physicochemical properties 
of free cyclodextrin molecules are different from those in the complex. In theory, any 
methodology that can be used to observe these changes in addition physicochemical 
properties may be utilized to determine the stoichiometry of the complexes formed 
and numerical values of their stability constants. These include changes in solubility, 
changes in chemical reactivity, changes in UV/Vis absorbance, changes in 
fluorescence, NMR chemical shift, changes in drug retention (e.g., in liquid 
chromatography), changes in pka values, potentiometric measurement, changes in 
chemical stability and effects on drug permeability through artificial membranes. 
Furthermore, since complexation will influence the physicochemical properties of the 
aqueous complexation media, methods that monitor these media changes can be 
applied to study the complexation. 
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For  example,  measurements  of  conductivity  changes,  determination  of 
freezing point depression, viscosity measurements and calorimetric titration’s. 
However, only few of these methods can be applied to obtain structural information 
on drug/ cyclodextrin complexes. 
 
 
1.7.   Stability Studies:  
 
(Lachmann L. and Herbert A. Libberman., 1991) 
 
Stability  of  a  drug  can  also  be  defined  as  the  time  from  the  date  of 
manufacture and packaging of the formulation until its chemical or biological activity 
is  not  less  than  a  predetermined  level  of  labeled  potency  and  its  physical 
characteristics have not changed appreciably or deleteriously. The environmental 
factors, ingredients used and the nature of the container can affect stability. 
Loss of potency usually occurs from a chemical change, the most common 
reaction being hydrolysis, oxidation and reduction. Potency is determined by means 
of assay procedure that differentiated between the intact drug and its degradation 
product. 
Accelerating the decomposing process and extrapolating the result to normal 
storage conditions may make a prediction of the life of the product. Acceleration of 
chemical decomposition is achieved by raising the temperature of the preparations. 
Application of the principles of chemical kinetics to the results of accelerated storage 
test carried out at three or more elevated temperatures enable prediction to be made of 
the effective life of the preparation at normal temperature. 
 
Plotting the appropriate function of concentration against time and obtaining a 
linear relationship determine the order of the reaction for the decomposition process. 
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The reaction velocity constant k for the decomposition at each of the elevated 
temperature  can  be  calculated  from  the  slope  of  the  line.  The  most  satisfactory 
method  for  expressing  the  influence  of  temperature  on  reaction  velocity  is  the 
quantitative relation proposed by Arrhenius. 
 
 
–Ea/RT 
Where,                                K = Ae 
 
 
K = Specific rate of degradation. 
 
 
R = Gas Constant (1.987 cals/deg/mol) 
T = Absolute temperature.  
A = Frequency factor.  
 
 
Ea = Energy of activation.  
 
 
The Arrhenius relationship is then employed to determine the ‘K’ value for 
decomposition at room temperature. This is obtained from the linear plot of the 
logarithm of ‘k’ value against reciprocal of absolute temperature, which is then 
extrapolated to room temperature (25° C). The value of ‘K’ at 25° C may be then 
substituted in the appropriate rate equation and an estimate obtained of the time 
during which the product will maintain the required quality or potency (shelf- life). 
The table below indicates maximum time and minimum time at which potency 
must be at least 90 % of label claim at the temperature indicated in order to predict a 
shelf- life of two years at room temperature. 
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Table 1.2: Stability requirement for maintenance of shelf- life 
 
 
Temperature° C 
 
Maximum time 
 
Minimum time  
 
37° C 
 
12 months 
 
6.4 months. 
 
45° C 
 
8.3 months 
 
2.9 months. 
 
60° C 
 
4.1 months 
 
3 weeks. 
 
85° C 
 
6 weeks 
 
2.5 days 
 
 
 
If the assay is over 90 % of original potency at the minimum time (with 
activation energy 20 K cals/mol) at the respective temperature, in all probability the 
assays will be over 90 % after two years at room temperature. If the assay remain 
over 90 % at the maximum time shown (with activation energy 10 K cals/mol) it is 
certain that a potency of over 90 % will be maintained after two years at room 
temperature. 
1.8.   Applications of Cyclodextrins: 
 
 
(Higuchi T. and Connors K.A., 1965; Rao B.P et al., 2007; Suresh S et al., 2004) 
 
 
™ β-Cyclodextrin Inclusion Complexes: 
 
 
Bioavailability Enhancement: Drugs with poor bioavailability typically have low 
water solubility and/or tend to be highly crystalline. As cyclodextrins is water soluble 
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and form inclusion complexes with apolar molecules or functional groups in water 
insoluble compounds. 
 
The resulting complex hides most of the hydrophobic functionality in the interior 
cavity of the cyclodextrin while the hydrophilic hydroxyl groups on its external 
surface remain exposed to the environment. The net effect being a water-soluble 
cyclodextrin-drug complex. In addition to improving solubility, cyclodextrins also 
prevent crystallization of active ingredients by complexing individual drug molecules 
so that they can no longer self-assemble into a crystal lattice. 
 
Active Stabilization: For an active molecule to degrade upon exposure to radiation, 
heat,  oxygen  or  water, chemical  reactions  must  take  place.  When  a  molecule  is 
constrained  within  the  cyclodextrin  cavity,  it  is  difficult  for  reactants  (water  or 
oxygen) to diffuse into the cavity and react with the protected guest. In the case of 
thermal or radiation induced degradation, the active must undergo molecular 
rearrangements. Again, due to the steric constraints on the guest molecule within the 
cavity, it is difficult for the active to fragment upon exposure to heat or light or if it 
does fragment, the fragments do not have the mobility needed to separate and react 
before a simple recombination takes place. 
 
Odour or Taste Masking: Through encapsulation within the cyclodextrin cavity, 
molecules or specific functional groups that cause unpleasant tastes or odours are 
hidden from the sensory receptors. The resulting formulations have no or little taste or 
odour and are much more agreeable to the patient.  
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Compatibility Improvement: Often one would like to combine multiple ingredients 
or  drug  actives  within  a  single  formulation  due  to  the  potential  for  synergistic 
benefits. However, different drugs are often incompatible with each other or another 
inactive ingredient within a formulation. Encapsulating one of the incompatible 
ingredients within a cyclodextrin molecule stabilizes the formulation by physically 
separating the components in order to prevent chemical interaction. 
 
Material Handling Benefits: Active ingredients that are oils/ liquids or are volatile 
materials can be difficult to handle and formulate into stable solid dosage forms. 
Encapsulating these types of substances in a cyclodextrin converts them to a solid 
powder that has good flow properties and can be conveniently formulated into a tablet 
by conventional production processes and equipment. 
 
Irritation Reduction: Active ingredients that irritate the stomach, skin or eye can be 
encapsulated within a cyclodextrin to reduce their irritancy. The formation of an 
inclusion complex reduces the local concentration of free active ingredient below the 
irritancy threshold. As the complex gradually disassociates, the active ingredient is 
absorbed  into  the  body  for  therapeutic  benefits,  but  its  local  free  concentration 
remains below levels that might be irritating. 
 
Oral Drug Delivery System: Rapid dissolving complexes with cyclodextrin have 
also been formulated for buccal and sublingual administration in this type of drug 
delivery system a rapid increase in the systemic drug concentration takes place along 
with the avoidance of systemic and hepatic first pass metabolism such as enhanced 
solubility of the ofloxacin drug. 
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Industrial Applications: Cyclodextrin change the physical and chemical properties 
of organic compounds. By this unique characteristic, cyclodextrins are used 
extensively in pharmaceutical, food and other industries for the following purpose: 
 
• Suppression of volatility of volatile compounds. 
 
 
• Stabilization of labile components decomposed and denatured by oxidation, UV- 
irradiation, hydration, heating, freezing and drying.  
 
• Drying assistance of humid or liquid food extracts, seasoning and beverages.  
 
 
• Reduction of bad taste and odour. 
 
 
•  Emulsification  of  oily  material,  solubilization  water- in-soluble  substances  and 
removal of non-volatile compounds from food. 
 
Potential Applications of β-Cyclodextrin: Cyclodextrin iodine complexes (CDS) by 
Nippon Chemical Co. Ltd., Japan are antibacterial deodorants, wrapping iodine in 
cyclodextrin cavity. CDIs possess powerful antibacterial activity with broad spectrum 
β-cyclodextrin iodine complexes are used in powder formulation. 
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2.  LITERATURE SURVEY 
 
 
2.1. Literature Review: 
 
 
Recent advancements in Inclusion complexes: 
 
 
1.   Akbari B.V et al., (2011) had developed cyclodextrin complexes to increase 
the solubility,  and  dissolution  rate  of  Rosuvastatin  Calcium (RST),  a  poorly  
water- soluble  3-hydroxy3-methyl  glut,  aryl  (CoA  (HMG-CoA)  Reductase  
inhibitor through inclusion complexation with β–cyclodextrin (β-CD).   The 
inclusion complexes were prepared by three different methods viz. physical, 
kneading, Co- evaporation and precipitation method.  The inclusion complex 
prepared with β–CD by kneading method exhibited greatest enhancement in 
solubility and fastest dissolution (98.96 % RST release in 30 min) of RST. 
 
2.   Vavia P.R et al., (1999) focused on inclusion complexation of ketoprofen with 
β– cyclodextrin (β-CD) and hydroxypropyl β–cyclodextrin (HP-β-CD).   The solid 
complexes were prepared by various methodologies such as physical mixture co- 
precipitation, kneading and freeze drying.  The drug and cyclodextrins were used 
in molar ratio of 1:1.  Freeze drying method was found to be the method of choice 
for successful inclusion complexation of ketoprofen with β-CD and HP-β-CD. 
 
3.   Bushetti S.S et al., (2009) the work was to improve the solubility, dissolution 
rate and antibacterial activity of drug by formulating its inclusion complexes with 
β- cyclodextrin and hydroxyl propyl β-cyclodextrin by kneading and physical 
mixture methods.  Drug release profile was studied in 7.2 pH phosphate buffer.  
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The results showed that an improvement in the antibacterial activity of the drug 
in its inclusion complex with hydroxyl propyl β-cyclodextrin in 1:3 molar ratio. 
 
4.   Patil J.S. et al., (2010) studied about orally administered drugs completely absorb 
only when they show fair solubility in gastric medium and such drugs shows good 
bioavailability.   Solid dispersion, solvent deposition, micronization are some vital 
approaches routinely employed to enhance the solubility of poorly water soluble 
drugs.   Cyclodextrins, the unique cyclic carbohydrates are successfully utilized as 
the potential complexing agents which form inclusion complex with insoluble drugs 
of various techniques have been investigated to explain the methods for preparation 
of inclusion complexes.   In the present review, an attempt was made to discuss 
various complexation techniques and tried to briefly highlight the potential 
applications, technical and economical limitations associated with these approaches. 
 
5.   Ramink singh et al., (2010) A review conducted on CD, cyclodextrins are cyclic 
oligosaccharides which have recently been recognized as useful pharmaceutical 
excipients. The molecular structure of these glucose derivatives generates a 
hydrophilic exterior surface and a non polar cavity interior.  Such cyclodextrins can 
interact  with  appropriate  size  drug  molecules  which  lead  to  the  formation  of 
inclusion complexes. The characterization of inclusion complexes was done with a 
purpose to determine the interaction of drug molecules with cyclodextrins which 
confirm the formation of inclusion complexes. 
 
6.   Swaroop S. et al., (2007) were formulated the inclusion complex of curcumin with 
 
β-cyclodextrin  (β-CD)  has  been  characterized  by  absorption  and  fluorescence 
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spectroscopy. From temperature-dependent fluorescence measurements, the 
thermodynamic  parameters  ∆H  and  ∆S,  for  the  complexation  were  estimated. 
Kinetics of binding was studied by stopped flow technique, from which the binding 
constant for inclusion complex was estimated.  Further, influence of such inclusion 
complex on change in superoxide radical scavenging property of curcumin was 
examined using xanthine/xanthine oxidase assay. 
 
7.   Guowang Diao et al., (2006) A research work on CD, β-Cyclodextrin can react with 
nitrobenzene to form an inclusion complex which is characterized by 'H NMR and 
power X-ray diffractometry.   The ratio of β-CD to NB in inclusion complex is 
determined as 1:1.  At 25° C, the dissociated constant, KD, of the inclusion complex 
is measured as 6.5 x 10-3 M in neutral solution (pH=7.0), but in alkali (pH=13.5), KD 
 
is 3.2 x 10-2 M which is much larger than that measured in neutral. 
 
 
8.   Shewale B.D et al., (2008) were examined the effect of pH and concentrations of 
hydroxyl propyl β-cycloedextrin on the solubility of carvedilol as it shows pH- 
dependent solubility.  But inclusion in the cavity of hydroxyl propyl-β-cyclodextrin 
might depend upon charge state of the molecule.   So it can be concluded that 
solubility of carvedilol, can be increased either by the addition of hydroxypropyl-β- 
cyclodextrin or by adding pH lowering agents.  But both these methods if are to be 
used together, pH should be selected carefully.  
 
9.   Indap M.A et al., (2002) had suggested hydroxyl propyl beta cyclodextrin complex 
was able to protect bone marrow cells from lethal effect of radiation.   When the 
cytotoxicities of quercetin and its complexes were compared on erythrocytes of rat 
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and rabbits, no significant differences were observed.   The ability to selectively 
target quercetin via its cyclodextrin inclusion complex against cancer growth could 
improve the therapeutic effectiveness of cyclodextrin preparations as well as reduce 
adverse side effects associated with quercetin.   The new cyclodextrin inclusion 
complex appears to have high potential for the treatment of leukemia’s and possibly 
also for solid tumors. 
 
10. Chowdary  K.P.R  et  al.,  (2002)  the  complex  formation  of  nifedipine  with  β- 
cyclodextrin and hydroxyl propyl β-cyclodextrin was studied.  The phase solubility 
studies  indicated   the   formation   of   a   nifedipine-β-cyclodextrin   (1:1   M)   and 
nifedipine-hydroxypropyl  β-cyclodextrin  (1:1  M)  inclusion  complexes  with  a 
stability constant of121.9M-1 and 253.7M-1 respectively. 
 
11. Chowdary K.P.R et al., (2006) tested the solubility and dissolution rate of celecoxib 
were markedly enhanced by complex with β-cyclodextrin and hydroxyl propyl-β- 
cyclodextrin. Celecoxib-hydroxypropyl-β-cyclodextrin  (1:2)  inclusive  complex 
gave a 36.57-fold increase in the dissolution rate of celecoxib.   Addition of 
polyvinylpyrrolidone results in higher complexation efficiency and markedly 
enhanced solubilizing    efficiency    of    β-cyclodextrin    and    hydroxypropyl-β- 
cyclodextrin. 
 
12.  Jagtap Rajesh S. et al., (2009) enhanced the solubility and impart a controlled 
release  in  a  single  formulation.    Glipizide,  an  oral  hypoglycemic  agent  which 
belongs to Class II of BCS with relatively short elimination half life (2-4 hour) was 
complexed with β-cyclodextrin.  The dissolution study of kneading complex shows 
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significant increase in the drug release from kneading complex than pure drug and 
physical  mixture.  The  formulation  F3  having  Similar  dissolution  profile  like 
marketed preparation (GLUCOTROL XL) which having 50 mg of PEO.  Finally it 
can be concluded from the study that molecular complex with β-CD play a vital to 
obtain a uniform, controlled and complete drug release of a poorly soluble drug from 
the swellable / erodible matrix tablet. 
 
13. Sanoferjan A.M et al., (2000) had formulated the cyclodextrin complexation of 
tenoxican was attempted to enhance the solubility features of the drug.  The complex 
prepared in 1:1 M ratio by various techniques was evaluated for its dissolution 
profile, thermal stability and photostability.  The complex prepared by neutralization 
method was found to yield very reliable and best results over that of the common 
solvent and kneading method. 
 
14. Ramana M.V et al., (2008) showed that enhanced dissolution rate of rofecoxib in 
both media from betacyclodextrin complex and the further enhancement of 
dissolution was found in presence of ascorbic acid and citric acid and thus 
betacyclodextrin enhances the solubility by creating the acidic environment around 
the drug molecule, solubility of rofecoxib could be enhance further, which in turn 
would enhance the absorption of rofecoxib and produced greater pharmacological 
activity. 
 
15. Deshmukh S.S et al., (2007) made an attempt to prepare and characterized inclusion 
complexes of ziprasidone HCl with β-cyclodextrin and     HP-β-cyclodextrin.  The 
phase solubility analysis indicated that the formation of 1:1 molar inclusion complex 
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of a drug with β-cyclodextrin and HP-β-cyclodextrin.  The inclusion complexes were 
prepared co-precipitation, kneading and microwave method.    The prepared 
complexes were characterized using solubility study, DSC and XRD.  The inclusion 
complexes  prepared  with  HP-β-cyclodextrin  by  microwave  method  exhibited 
greatest enhancement in solubility and fastest dissolution of ziprasidone HCl. 
 
16.  Sarasija Suresh  et al., (2006) made an attempt to enhance the solubility features o f 
the drug.  Carbamazepine β-cyclodextrin complex prepared by kneading method was 
used  to  produce  dispersible  tablets.  A  23   factorial  design  was  employed  to 
investigate the effect of factors such as amount of binder, hardness and type of 
disintegrant on the tablet disintegration time and dissolution rate.   The three main 
factors studied had a significant influence on both response parameters. 
 
17. Sanjula Baboota et al., (2005) have prepared inclusion complexes of rofecoxib by 
using dimethyl β-cyclodextrin.  Complexes were prepared by physical, kneading and 
spray drying methods.  The release profile of the drug from complexes were studied 
in pH 1.2 and pH 7.4 and it was found that the marketed preparations showed lesser 
release characteristic as compared to the complex prepared by kneading method. 
 
18. Aithal K.S et al., (2005) had prepared the complexes of the norfloxacin with β-CD 
and enhanced UV absorption (a=3 times) and fluorescence emission (k=4 times) was 
observed. The 1:1 M neutralization complex gave maximum values of both UV 
absorption and fluorescence emission compared to physical mixture or kneading 
complex. 
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19. Dhaneshwar S.R et al., (2004) had prepared the methotrexate pro-drugs of α and γ - 
cyclodextrin.  The primary hydroxyl group of α and γ-cyclodextrin block the acidic 
group and the hydrolysis of cyclodextrin conjugates in colon is confirmed by 
hydrolysis kinetic studies in rat fecal material and the conjugate showed good 
masking ulcerogenic potential of free drug.  
 
20. Nagesh Bandi et al., (2004) had determined whether budesonide and indomethacin 
HPβ-CD complexes could be formed using a supercritical fluid process.  The process 
involved the exposure of drug-HP-β-CD mixtures to supercritical carbon dioxide. 
The ability of supercritical fluid process to form complexes was assessed by 
determining drug dissolution, drug crystallinity and drug excipients interactions. 
Thus budesonide and indomethacin HP-β-CD complexes with enhanced dissolution 
can be formed using a single step organic solvent free SCF process. 
 
21.  Sanjula  Baboota  et  al.,  (2005)  had  developed  the  inclusion  complexes  of 
meloxicam with β-cyclodextrin by various methods like grinding, kneading, solid 
dispersion and freeze-drying.   The in-vitro dissolution rate of drug β-cyclodextrin 
complex was faster compared to the drug alone. 
 
22.  Saha RK et al., (2002) had prepared inclusion complexes of nimesulide with β- 
cyclodextrin by solvent evaporation method and solid dispersion of nimesulide and 
ibuprofen by using various hydrophilic excipients (PEG-6000, sorbitol, PVPK-30, 
MCC).   Solid dispersion of nimesulide with PEG-6000 enhanced the solubility of 
nimesulide  more  than  1000  %.  The  dispersion  of  ibuprofen  in  sorbitol  showed 
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maximum  enhancement  of  solubility  up  to 75  %.    The  inclusion  complexes  of 
nimesulide in β-cyclodextrin also increase the solubility by 663 %. 
 
23.   Dalmora M.E et al., (2001) evaluated the topical formulations of piroxicam by 
determination of their in vitro release and in vivo anti- inflammatory.  Piroxicam was 
incorporated in ME (micro emulsion) and in the combined system β-cyclodextrin / 
ME, respectively relative to the buffered piroxicam (42.2 %).   These results 
demonstrated that micro emulsion induced prolonged effects, providing inhibition of 
the inflammation for 9 days after a single dose administration. 
 
Literature Review on Selected drug Aceclofenac: 
 
 
24. Thiyagarajan Ayyappan et al., (2009) had formulated the solid dispersion tablet 
formulation of Aceclofenac, a novel non steroidal anti inflammatory drug mainly 
used for rheumatoid arthritis osteoarthritis and ankylosing spondylitis.  Aceclofenac 
solid dispersion with crosspovidone showed maximum drug release and hence, the 
tablet formulation containing Aceclofenac, crosspovidone and polyvinyl pyrolidone 
K-30 solid dispersion, was prepared with a view to improve its water solubility.  The 
drug profile was studied in 2 % w/v sodium lauryl sulphate in Distilled water.  F-III 
gave far better dissolution than other laboratory developed formulations. The 
formulation was found to be stable for 30 days at 40° C± RH 75 % as per ICH 
guidelines, with insignificant change in the hardness, disintegration time, and in vitro 
drug release pattern. 
 
25. Kamal Dua et al., (2011) had developed and compared the stability of the β-CD 
 
dimer-Aceclofenac  complex  with  β-CD  monomer-Aceclofenac.  Such  molecular-  
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modeling studies can be employed as an additional tool to support the formation of 
stable molecular inclusion complexation of any water insoluble drug complexed with 
cyclodextrins. 
 
26. Dahiya S. et al., (2006) was prepared and characterized the binary systems of 
Acelofenac (AC) with hydroxypropyl beta-cyclodextrin (HP-β-CD) in equimolar 
ratio.  Solid binary systems of Aceclofenac with HP-β-CD were prepared using co 
grinding,  kneading,  and  co  evaporating  methods,  and  a  physical  mixture  was 
prepared for comparison.   All the binary systems showed superior dissolution and 
lower dose: solubility ratio (D: S ratio) as compared to pure AC.  It was suggested 
that complexation of Aceclofenac with HP-β-CD may be used as an approach to 
change the drug from Biopharmaceutics Classification System BCS Class II to BCS 
Class I without changing its intrinsic permeability. 
 
27.  Gajendran P. et al., (2010) tested the phase solubility profile of Aceclofenac with 
beta-cyclodextrin (β-CD)   prepared   by   kneading   method   and   those   were 
characterized by X-ray diffraction and FTIR spectra.  The complexes were prepared 
as tablets with and without sodium starch glycolate (2 %) (SSG) as super 
disintegrants. Precompression parameters like tapped density, Carr’s index, bulk 
density and angle of repose were determined.   The order of faster dissolution rate 
observed in various ratios with SSG was 1:2 complex > 1:1 complex >2:1 complex > 
pure drug, in acidic medium contains 1 % SLS.  Another batch was also prepared in 
the same ratio with β-CD, this batch have higher solubility of Aceclofenac when 2 % 
SSG added; the release was 30 min faster in 1:2 pH medium containing 1 % sodium 
lauryl sulphate (SLS) from the above result we conclude the inclusion complex of 
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drugs and β-CD ratio 1:2 with SSG as superdisintegrate could be used as an effective 
technique for immediate release of Aceclofenac. 
 
28. Kulkarni N.S et al., (2010) carried out research work by developing the inclusion 
complexation of Aceclofenac with beta-cyclodextrin by grinding, microwave and 
spray drying techniques. The samples were subjected to in vitro dissolution studies, 
fourier transform infra-red spectroscopy, DSC, NMR and X-ray diffraction studies. 
They were reported in vitro dissolution of Aceclofenac-hydroxy propyl-beta- 
cyclodextrin complex was faster as compared to the Aceclofenac-beta-cyclodextrin 
complex and Aceclofenac alone. 
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2.2. DRUG PROFILE 
 
 
 
(IP., 2007; BP., 2009; Kabir., et al., 2009; Merck index., 2006) 
 
 
ACECLOFENAC: 
 
 
Aceclofenac is a potent non-steroidal anti- inflammatory drug. Due to its 
preferential cox-2 blockade it has better safety than conventional NSAIDs with respect to 
adverse effects on gastro intestinal and cardiovascular system. 
 
IUPAC Name            :          2-[(2, 6-Dichlorophenylamino) phenyl] acetoxy acetic acid. 
 
 
Description                :          A white to almost white crystalline powder. 
 
 
Structure                   : 
 
 
 
 
 
Fig. 2.1: Structure of Aceclofenac 
 
 
Molecular formula   :          C16H13Cl2NO4 
 
 
Molecular weight      :          354.2 
 
 
Category                    :          Non-steroidal anti inflammatory drug. 
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Solubility :              It is practically insoluble in water; soluble in alcohol and 
methyl alcohol; It is freely soluble in acetone and dimethyl 
formamide. 
 
Melting point            :          149 - 153° C 
 
 
Pharmacology: 
 
 
1.  Aceclofenac directly blocks PGE2 secretion at the sight of inflammation by inhibiting 
 
IL- Beta TNF in the inflammatory cells. (Intracellular action) 
 
 
2.  Aceclofenac stimulates the synthesis of the extra cellular matrix of the human articular 
cartilages. 
 
3.  Inhibits neutrophil adhesion and accumulation at the inflammatory sites in the early 
phase and thus blocks the pro- inflammatory action of neutrophil.  
4.  Aceclofenac has higher COX2 specificity than diclofenac sodium. 
 
 
 
 
 
.    Fig. 2.2: Pathway describing general anti- inflammatory action of Aceclofenac 
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Pharmacokinetics: 
 
 
Aceclofenac is rapidly and completely absorbed after oral administration, peak 
plasma concentration is reached 1 to 3 hours after an oral dose. The drug is highly protein 
bound. The presence of food does not alter the extent of absorption of Aceclofenac but 
the    absorption    rate    is    reduced.    It    is    metabolized    to    a    major    metabolite 
4-hydroxyAceclofenac and to a number of other metabolites including 5–Hydroxy 
Aceclofenac,   4-Hyrodxydiclofenac,   Diclofenac   and   5-Hydroxydiclofenac.   Renal 
excretion is the main route of elimination of Aceclofenac with 70 to 80 % of an 
administered dose found in the urine, mainly as the glucuronides of Aceclofenac and its 
metabolites of each dose of Aceclofenac, 20 % is excreted in the faeces. The plasma 
elimination half life of the drug is approximately 4 hours. 
 
Drug interactions: 
 
 
Aceclofenac may increase plasma concentrations of lithium, digoxin and 
methotrexate, increase the activity of anticoagulant, inhibits the activity of diuretics, 
enhance cyclosporine nephrotoxicity and precipitate convulsions when co-administered with 
quinolone antibiotics. Furthermore, hypo or hyperglycemia may result from the 
concomitant administration of Aceclofenac and antidiabetic drugs, although this is rare. 
The co-administration of Aceclofenac with other NSAIDs results in increased frequency 
of adverse event. 
 
Adverse drug interactions: 
 
 
Aceclofenac  is  well  tolerated  with,  most  adverse  events  being  minor  and 
reversible and affecting mainly the G.I system. Most common events include dyspepsia 
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(7.5 %), abdominal pain (6.2 %), nausea (1.5 %), diarrohoea (1.5 %), flatulence (0.8 %), 
gastritis (0.6 %), constipation (0.5 %), vomiting (0.5 %), and pancreatitis (0.1 %). Other 
adverse effects which is not common such as dizziness (1 %), vertigo (0.3 %), and rare 
cases of paraesthesia and tremor. 
 
Dosage and administration  :          The usual dose of Aceclofenac is 100 mg given 
 
 
twice daily by mouth, one tablet in the morning and 
one in the evening. 
 
Storage                                  :         In an air tight container, protected from light. 
 
 
Uses                                        :          Aceclofenac is used in the treatment of 
Osteoarthritis, rheumatoid arthritis, ankylosing 
spondylitis, dental pain, post operative pain, 
dysmenorrhoea, acute lumbago, musculoskeletal 
trauma and gonalgia (knee pain). 
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2.3. β-CYCLODEXTRIN PROFILE 
 
 
(Raymond C.Rowe., 2003) 
 
 
β-CYCLODEXTRIN: 
 
 
Synonyms :          Beta-cycloamylose; betadex; beta-dextrin; cyclohepta 
amylase; Cycloheptaglucan: cyclomaltoheptose; kleptose. 
 
Functional category :          Solubilizing agent and stabilizing agent. 
 
 
Empirical Formula   :          C42 H70O35 
 
 
Molecular Weight     :          1135. 
 
 
 
 
 
Fig.2.3: Structure of β-Cyclodextrin 
 
 
Description :          White, practically odorless, amorphous powder, having a 
slightly sweet taste. 
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Solubility :          Soluble in 1 in 200 part of propylene glycol, 1 in 50 
of water at 20° C, 1 in 20 at 50° C. 
 
Stability and storage conditions:    Stable in the solid state if protected from high 
humidity, should be stored in a tightly sealed 
container in cool, dry place. 
 
Safety                                     :          Used in oral pharmaceutical formulations. 
 
 
Handling Precaution            :          It should be handled in a well-ventilated 
environment efforts should be made to limit the 
generation of dust, which can be explosive.  
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3.  AIM AND OBJECTIVE  
 
 
 
 
 
The poor aqueous solubility and dissolution of relatively insoluble drugs has 
been a major problem for a long time in the formulation of oral dosage form.  So in 
the   recent   years   much   attention   has   been   focused   on   the   problem   of   drug 
bioavailability.  The dissolution rate of a drug from its dosage form now considered as 
an important parameter in bioavailability,  dissolution is the rate limiting step in the 
absorption of the drug from solid dosage forms, especially when the drug is poorly 
water soluble.  Among the various approaches to improve the dissolution of the drugs, 
the preparation  of cyclodextrin  inclusion  complexes  has often proven to be highly 
successful. 
 
It has short biological  half-life  (4 to 4.3 hours),  and the usual oral dosage 
regimen is 100 mg taken 2 times a day.   The basic goal of therapy is to achieve a 
steady state blood or tissue level that is therapeutically effective and non-toxic for the 
treatment period of time. 
 
Aceclofenac  is Nonsteroidal  anti-inflammatory  drug (NSAID).   It is phenyl 
acetic acid derivative showing effective anti-inflammatory, analgesic and anti-pyretic 
properties mainly used in osteoarthritis and rheumatoid arthritis. 
 
Aceclofenac is practically insoluble in water. Its aqueous solubility is reported 
as 0.53 mg/ml.  The aqueous solubility of drug is improved by various techniques like 
solid dispersions, micronization, solvent deposition, use of surfactants and inclusion 
complexation etc. 
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In the present work, was aimed to prepare and characterize the inclusion 
complexes  of Aceclofenac  with cyclodextrins  in different molar ratios by different 
methods such as physical, kneading and common solvent method. 
 
Preparation of inclusion complex using cyclodextrin for its ready water- 
solubility, significant potential for solubilization and good safety profile. 
 
The potential applications of Aceclofenac inclusion complexes: 
 
 
¾   May minimize the frequent dosing intervals.  
 
¾    Prolong the pharmacological effect. 
 
¾   May help to improve patient compliance by reducing the gastrointestinal side 
effects like peptic ulcer etc., 
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4.  PLAN OF WORK 
 
 
 
 
 LITERATURE SURVEY 
  SELECTION OF DRUG AND β-CYCLODEXTRIN 
  PROCUREMENT OF DRUG AND β-CYCLODEXTRIN 
 EXPERIMENTAL WORK 
 Preformulation Study 
 
 Identification of Drug 
 
€ Organoleptic Properties 
 
€ Determination of Melting Point 
 
€ Solubility Study 
 
€ Loss on Drying 
 
€ FTIR 
 
€ UV Spectrophotometric Study in Methanol 
 
€ UV Spectrophotometric Study in Distilled Water 
 
€ Assay of Aceclofenac 
 
   Formulation of complexes with β-Cyclodextrin 
 
€ Kneading method 
 
€ Common Solvent method 
 
€ Physical mixtures 
 Evaluation of inclusion Complexes 
 
 Phase Solubility Studies 
 
€ UV Spectrophotometric Study of Prepared Inclusion Complexes 
 
€ Fourier Transform Infrared (FTIR) Spectroscopy 
 
€ Differential Scanning Calorimetry (DSC) Analysis 
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€ X-ray Diffraction Studies 
 
€ Drug Content Estimation 
 
€ In vitro Dissolution Studies 
 
€ Stability Studies 
 
 RESULTS AND DISCUSSION 
 SUMMARY AND CONCLUSION 
 FUTURE PROSPECTUS 
 BIBLIOGRAPHY 
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5.  MATERIALS AND EQUIPMENTS 
 
 
 
 
 
 
 
5.1. Materials Used: 
 
 
Table 5.1: List of raw materials with source 
 
S. No Name of Ingredients  Name of supplier 
1 Aceclofenac Tristar Pharmaceuticals, Puduchery. 
2 β - Cyclo dextrin Alkem laboratories pvt ltd, Mumbai. 
3 25 % ammonia Qualigens fine chemicals, Mumbai. 
4 Calcium chloride Qualigens fine chemicals, Mumbai. 
5 Methanol Qualigens fine chemicals, Mumbai. 
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5.2. Equipments Used: 
 
 
Table.5.2: List of equipments with model/make 
 
 
 
S. No Equipment Model/ Make 
 
1 Electronic balance Shimadzu BL-220H. 
 
2 Hot air oven Chemi Equipments, Bombay. 
 
3 
USP tablet dissolution apparatus 
 
Type I 
 
Veego scientific VDA-8DR. 
 
4 
 
UV spectrophotometer 
 
Shimadzu-1700 Pharmaspec. 
 
5 FTIR spectrophotometer JASCO FT/IR-5300 
 
6 
 
Differential scanning calorimeter 
 
Shimadzu DSC 60, Japan. 
 
7 
 
Rotary Shaker 
 
Remi Electrical 
 
8 
 
pH Meter 
 
Elico Li-120 
 
9 
 
Melting Point Apparatus 
 
Guna Enterprises, Chennai.  
 
10 
 
Standard sieve (40 #) 
 
Jayant scientific, IND. 
 
11 
 
X-ray Diffractometer 
 
X-ray Diffractometer PW-1710 
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6. PREFORMULATION STUDY 
 
 
 
 
6.1. Identification of Drug: 
 
The preliminary studies were carried out by testing of different physical and 
chemical properties of drug as follows. 
6.1.1. Organoleptic properties:                                             (Lachman L. et al., 1991) 
 
The Organoleptic properties like physical state, colour, odour etc., of the drug 
was reported with help of the descriptive terminology. It helps to identify the drug. 
6.1.2. Melting point: 
 
(IP., 2007) 
 
It is the easy way to identify the drug. The melting point of Aceclofenac was 
tested by use of a laboratory melting point apparatus with a procedure given in the 
Indian Pharmacopeia 2007. 
6.1.3. Solubility study: 
 
(IP., 2007) 
 
The  solubility  of  Aceclofenac  was  determined  by  micropipette  method  in 
various solvents in order to meet the official standards. 
6.1.4.   Loss on drying: 
 
(IP., 2007) 
 
Loss on drying is the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The test can be carried out on the well mixed sample of the substance. 
 
Initial weight of substance – Final weight of substance 
Loss on drying = --------------------------------------------------------------------       x 100 
Initial weight of substance 
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6.1.5. FTIR spectroscopy: 
 
The infrared spectrum  was generally  used as an identification  parameter  to 
know the chemical structure of drugs. For the FTIR spectrum of Aceclofenac, FTIR 
spectrophotometer was used. 
A small quantity of sample was mixed with sufficient potassium bromide and 
compressed into a pellet by applying a 10 tons pressure with help of a hand operated 
press. This pellet was kept in a sample holder and scanned from 4000 to 400 cm
-
1. 
6.1.6. UV spectrometric study in Methanol: 
 
¾   Determination of λmax: 
 
Weighed amount of Aceclofenac was dissolved in Methanol to obtain a 
 
1000 mcg/ml solution. This solution was subjected to scanning between 200- 
 
400 nm and absorption maximum was determined. The effect of dilution on 
absorption maxima was studied by diluting the above solution to 15 mcg /ml 
and scanned from 200-400 nm. The wave length of maximum absorbance was 
found to be 275 nm. 
 
¾   Preparation of standard curve of Aceclofenac in Methanol: 
 
(IP., 2007) 
 
The standard curve was prepared by dissolving 50 mg of Aceclofenac 
 
50 ml of   Methanol. In the stock solution 1 ml was withdrawn and diluted to 
 
25 ml of Methanol. It was further diluted with Methanol to get the solution in 
the   concentration   range   of   4-20   μg/ml.   The   absorbance   values   were 
determined at 275 nm. A graph of absorbance Vs concentration was plotted. 
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6.1.7. UV Spectrometric study in Distilled Water: 
 
 
¾   Preparation of standard curve of Aceclofenac in Distilled Water: 
 
(Rohit Shah et al., 2008) 
 
The standard curve was prepared by dissolving 50 mg of Aceclofenac 
in 50 ml of Methanol. In the stock solution 1 ml was withdrawn and diluted to 25 ml 
of Methanol.  It was further diluted with Distilled  Water to get the solution  in the 
concentration  range of 4-20 μg/ml.  The absorbance values were determined  at 274 
nm. A graph of absorbance Vs concentration was plotted. 
 
6.1.8. Assay of Aceclofenac: 
 
 
(IP., 2007) 
 
 
Accurately  weighed  the powder  equivalent  to 100 mg of Aceclofenac  was 
transferred to 100 ml volumetric flask and the volume was made up to the mark with 
Methanol. The mixture was filtered through whatmann filter paper No.41 and then 5 
ml of filtrate was transferred to 50 ml volumetric flask and made up to the mark with 
Methanol.1  ml aliquots  of the sample  were  transferred  and diluted  to 10 ml with 
Methanol to obtain strength as 10 µg/ml and then the absorbance was measured at 275 
nm against Methanol as blank. The percentage purity of the drug was calculated by 
using calibration graph method. 
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7.  FORMULATION OF INCLUSION COMPLEXES 
 
 
 
 
 
Table 7.1: Composition of inclusion complexes of Aceclofenac 
 
 
 
 
 
Method 
 
Formulation 
 
Code 
 
Drug to 
carrier 
Drug to 
carrier 
ratio  
 
Drug 
 
(g) 
 
β-Cyclodextrin 
 
(g) 
 
Kneading 
method 
F1 ACE : β-CD 1:1 1 1 
F2 ACE : β-CD 1:2 1 2 
F3 ACE : β-CD 1:3 1 3 
Common 
solvent 
method 
F4 ACE : β-CD 1:1 1 1 
F5 ACE : β-CD 1:2 1 2 
F6 ACE : β-CD 1:3 1 3 
 
Physical 
method 
F7 ACE : β-CD 1:1 1 1 
F8 ACE : β-CD 1:2 1 2 
F9 ACE : β-CD 1:3 1 3 
 
 
 
Where, 
 
 
ACE - Aceclofenac 
 
 
β-CD -  Beta-Cyclodextrin 
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7.1. Methods of Preparation of Inclusion Complexes: 
 
 
(Sanoferjan A.M., 2000; Chowdary K.P.R., 2000) 
 
 
Kneading method: 
 
 
β-Cyclodextrin  was taken in a glass mortar and little water was added and 
mixed  to obtain  a homogenous  paste.   Aceclofenac  was then  added  slowly  while 
grinding.  The mixture was ground for 1h during this process appropriate quantity of 
water was added to maintain suitable consistency.  The paste was dried in an oven at 
40º C for 48 hr.  The dried complex was taken for study. 
 
 
Common solvent method: 
 
 
Aceclofenac  and β-Cyclodextrin  were dissolved  in 25 % ammonia  and the 
solvent was allowed to evaporate overnight at room temperature.   The complex so 
prepared was pulverized and sifted through sieve no.80. 
 
Physical mixture: 
 
 
Previously weighted drug and β- cyclodextrin  mixture was blended in glass 
mortar for about an hour and passed through sieve no.85 to get physical mixture and 
stored in desiccator over fused calcium chloride. 
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8.  EVALUATION OF INCLUSION COMPLEXES 
 
 
 
 
8.1 Phase Solubility Studies: 
 
(Chowdary K.P.R., 2006 and Babu R.J., 2004) 
 
Phase solubility studies for Aceclofenac (ACE) complexes were performed to 
determine how the complexes of cyclodextrin affect the solubility of the Aceclofenac. 
These studies also determine  the stoichiometry  of drug:cyclodextrin  complexes  and 
numerical values of their stability constants.  
€ Phase solubility of Aceclofenac (ACE) with beta-cyclodextrin (β-CD) 
 
Procedure: 
 
For phase solubility studies of ACE, an excess of drug (200 mg) was added to 
 
20 ml portions of Distilled water, each containing variable amount of β-cyclodextrin 
 
-3 
such as 0, 1, 3, 6, 9, 12, and 15 x 10 
 
moles/liter. All the above solutions with variable 
 
amount of β-cyclodextrins were shaken for 72 hours. After shaking, the solutions were 
filtered and their absorbance was noted at 275 nm. The solubility of the ACE in every 
β-cyclodextrin  solution  was  calculated  and  phase  solubility  diagram  was  drawn 
between the solubility of ACE and different concentrations of β-cyclodextrin. 
The stability  constant  of ACE β-cyclodextrin  complex  was calculated  using 
 
Higuchi and Connor’s equation. 
 
 
K (1:1) =     Slope 
S0 (1-Slope) 
 
S  = Intrinsic solubility of ACE in aqueous complexation media (Distilled water) “slope” 
0 
 
was calculated from phase solubility diagram.  
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8.2. UV Spectrometric Study of Prepared Inclusion Complexes: 
 
(Rohit shah et al., 2008) 
 
Weighed accurately the quantity of inclusion complex equivalent to 50 mg was 
transferred  to 50  ml volumetric  flask  and volume  was  made  up to the  mark  with 
Methanol. The mixture was filtered through whatmann filter paper No.41 and then 5 
ml of filtrate was transferred to 50 ml volumetric flask and made up to the mark with 
Methanol.  From  the  resulting  solution  1ml  was  taken  and  diluted  with  10  ml  of 
Methanol to get a final concentration of 10 µg/ml. The sample solutions were scanned 
at 200-400 nm. 
 
8.3. Fourier Transform Infrared (FTIR) Spectroscopy: 
 
(Gajendran P. et al., 2010) 
 
Infrared spectroscopy  is one of the most powerful analytical  techniques  that 
offer  the  possibility  of chemical  identification.  The  IR  spectra  of  Aceclofenac,  β- 
cyclodextrin and inclusion complex were obtained by KBr pellet method by JASCO 
FT/IR-5300 spectrometer. 
 
8.4. Differential Scanning Calorimetry (DSC) Analysis: 
 
(Gajendran P. et al., 2010) 
 
The thermal behavior of Aceclofenac,  β-cyclodextrin  and inclusion  complex 
was studied using differential scanning calorimetry in order to confirm the formation 
of the solid complex. When guest molecule are incorporated in the cyclodextrin cavity 
or in the crystal lattice, their melting, boiling and sublimation points are usually shifted 
to a different temperature or disappear within the temperature range, where the 
cyclodextrin lattice is decomposed. 
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8.5. X-ray Diffraction Studies: 
 
(Srinivas Mutalik et al., 2008) 
 
The X-ray diffraction patterns of Aceclofenac, β-cyclodextrin and inclusion 
complex were reordered using Philips X-ray diffractometer  (Model: PW 1710) with 
copper target. The conditions were: voltage -30kV; current -30mA; scanning speed - 
1°/min; temperature  of acquisition;  room temperature;  detector: scintillation  counter 
detector; sample holder: non-rotating holder.  
 
8.6. Drug Content Estimation: 
 
(IP., 2007) 
 
Accurately weighed the quantity of inclusion complex equivalent to 100 mg 
of drug was transferred to 100 ml volumetric flask and the volume was made up to the 
mark with Methanol. The mixture was filtered through whatmann filter paper No.41 
and then 5 ml of filtrate was transferred to 50 ml volumetric flask and made up to the 
mark with Methanol.1 ml aliquots of the sample were transferred and diluted to 10 ml 
with Methanol to obtain strength as 10 µg/ml and then the absorbance was measured at 
275 nm against Methanol as blank. 
 
 
8.7. In vitro Dissolution studies: 
 
(IP., 2007) 
 
 
In  vitro  dissolution  of  Aceclofenac  inclusion  complex  was  studied  in  USP 
XXIV dissolution apparatus employing an apparatus I, 900 ml of Distilled water was 
used  as  dissolution  medium.     The  speed  of  rotation  was  set  at  50  rpm.    The 
temperature of dissolution media was previously warmed to 37±0.5° C and was 
maintained throughout the experiment.   1 ml of sample of dissolution medium were 
withdrawn at known intervals of time, filtered the solution and analyzed for the drug 
release by measuring the absorbance at 274  nm after suitable dilution with Distilled 
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Water. Then the volume withdrawn at each time interval was replaced with the fresh 
Distilled Water. The percentage amount of Aceclofenac released was calculated and 
plotted against time. 
 
Table 8.1: Parameters were used for the dissolution study 
 
 
Apparatus 
 
USP Dissolution  apparatus  
 
(Type I) 
 
Dissolution medium 
 
Distilled Water 
Temperature  37 + 0.5° C 
Volume  900 ml 
Speed 50 rpm 
Sample withdrawn 1 ml 
Running Time  60 min 
 
 
 
 
8.8 Stability Studies: 
 
(Sanoferjan AM et al., 2000) 
 
 
The formulation F2 was packed in dessicator, which were tightly plugged with 
cotton and capped. They were then stored at 25
° 
C at 60 % and 40
° 
C at 75 % RH for a 
period  of  three  months  and  the  samples  were  withdrawn  at  every  month  for  the 
estimation of drug content and in vitro dissolution studies. 
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9.  RESULTS AND DISCUSSION 
 
 
9.1. Identification of Drug: 
 
9.1.1. Organoleptic Properties: 
 
Colour           :  White or almost white powder 
 
Odour            :  Odourless 
 
Appearance    : White crystalline powder 
 
9.1.2. Melting Point: 
 
 
Melting  point  of  Aceclofenac  was  found  to  be  150.3±21°  C.  The  official 
melting  point  range  for  Aceclofenac  is between  149-153°  C.  Hence,  results  were 
complied the limits specified in official Book. 
 
9.1.3. Solubility Study: 
 
Table 9.1: Solubility of Aceclofenac in various solvents 
 
 
S. No. 
 
Solvents 
 
Extent of Solubility 
 
Inference 
1 Distilled Water 10 mg in more than 10 ml Insoluble  
2 Ethanol 10 mg in 160 µl Soluble  
3 Methanol 10 mg in 200 µl Soluble  
4 0.1N HCl 10 mg in more than 10 ml Insoluble  
5 0.1N NaOH 10 mg in more than 10 ml Insoluble  
6 Acetone 10 mg in 70 µl Freely soluble  
7 pH buffer 7.4 10 mg in more than 10 ml Insoluble  
8 Chloroform 10 mg in 400 µl Sparingly soluble  
 
 
The results were complied with the official book. 
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9.1.4. Loss on Drying: 
 
The percentage loss on drying after three hours was found to be 0.25 %. 
 
 
Table 9.2: Percentage loss on drying of Aceclofenac 
 
 
 
S. No. 
 
Percentage LOD 
Average 
percentage LOD 
1 0.25  
 
 
 
0.25 ± 0.01 2 0.26 
3 0.24 
 
 
The sample passes the test for loss on drying as per limit specified in IP 2007 
(NMT 1 %). 
 
9.1.5. FTIR spectroscopy: 
 
 
 
Fig 9.1: FTIR spectrum of Aceclofenac 
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Table 9.3: Characteristic frequencies in FTIR spectrum of Aceclofenac 
 
S. No Wave number(cm
-1
) Inference 
1 3316.41 N-H stretching  
2 3110.41 C-H stretch ing 
3 1626.63 C=O stretch ing  
4 1386.20 Aromat ic C-H stretching  
 
 
The drug was confirmed as Aceclofenac with results obtained from FTIR 
 
spectrum analysis.  
 
 
9.1.6. UV spectrophotometric study: 
 
 
¾   The absorption maximum for Aceclofenac in Methanol was found to be 275 
nm 
 
 
 
Fig. 9.2: λmax of Aceclofenac in Methanol 
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¾   The absorption maximum for Aceclofenac in Distilled Water was found to be 
274 nm 
 
 
 
Fig. 9.3: λmax of Aceclofenac in Distilled Water 
 
9.1.7. Calibration curve of Aceclofenac in Methanol: 
 
UV absorption spectrum of Aceclofenac in Methanol shows λ max at 
 
275 nm. Absorbance obtained for various concentrations of Aceclofenac are given in 
Table 9.4. The graph of absorbance vs concentration for Aceclofenac was found to be 
linear in the concentration range of 4 – 20 μg /ml. 
Table 9.4: Data of concentration and absorbance for Aceclofenac in Methanol 
 
 
S. No. 
Concentration 
 
(µg/ml) 
 
Absorbance(nm) 
1 0 0.000 
2 4 0.110 
3 8 0.209 
4 12 0.327 
5 16 0.414 
6 20 0.484 
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Fig. 9.4: Standard graph of Aceclofenac in Methanol 
 
 
 
 
 
 
Table 9.5:  Data for calibration curve parameter of Methanol 
 
 
S. No. Parameters Values 
1 Correlation coefficient (r) 0.999 
2 Slope  0.008 
3 Intercept 0.034 
 
 
 
9.1.8. Calibration curve of Aceclofenac in Distilled Water: 
 
UV absorption  spectrum  of Aceclofenac  in Distilled  Water shows λ 
max at 274 nm. Absorbances obtained from various concentrations of Aceclofenac in 
Distilled Water are given in Table 9.6. The graph of absorbance vs concentration for 
Aceclofenac was found to be linear in the concentration range of 4 – 20 μg/ml. 
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Table 9.6: Data of concentration and absorbance for Aceclofenac in Distilled Water 
 
S. No. Concentration (µg/ml) Absorbance (nm) 
1 0 0.000 
2 4 0.051 
3 8 0.112 
4 12 0.152 
5 16 0.195 
6 20 0.241 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.5: Standard graph of Aceclofenac in Distilled Water 
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Table 9.7:  Data for calibration curve Parameter of Distilled Water 
 
 
S. No. Parameters Values 
1 Correlation coefficient (r) 0.998 
2 Slope (m) 0.014 
3 Intercept(c) 0.064 
 
 
 
9.1.9. Assay of Aceclofenac: 
 
The  percentage  purity  of  drug  was  calculated  by  using  calibration  graph 
method (least square method). 
Table 9.8:  Assay of Aceclofenac 
 
S. No. Percentage purity (%) Avg. percentage purity (%) 
1 98.32  
 
 
99.69 ± 1.2095 2 100.16 
3 100.60 
 
*All the values are expressed as mean ± SD, n = 3. 
 
The percentage purity of raw material Aceclofenac was found to be 99.69 %. 
Hence, the sample declared as pure. 
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9.2. Phase Solubility Studies: 
Table 9.9: Phase solubility studies of Aceclofenac - β-cyclodextrin complexes 
 
 
Concentration of β-CD (mM) 
Concentrations of Aceclofenac* 
(mM) 
0 0.651 ± 0.026 
1 0.675 ± 0.045 
3 0.701 ± 0.062 
6 0.784 ± 0.027 
9 0.869 ± 0.035 
12 0.948 ± 0.042 
15 1.056 ± 0.039 
*All the values are expressed as mean ± SD, n=3. 
 
 
 
Fig. 9.6: Phase solubility studies of Aceclofenac - β-cyclodextrin complexes 
r
2 
- value = 0.991 
B- value (slope) = 0.026 
 
A- value (intercept) = 0.636 
 
Stability constant – K (1:1) =             Slope 
 
S0 (1 – slope) 
 
-3  
= 0.026 /0.636×10 
= 42.003. 
(1-0.026) 
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The phase solubility revealed a linear relationship between aqueous drug 
solubility with increase in β-cyclodextrin (r2= 0.991). The phase solubility results 
were shown in Table 9.9 and Fig. 9.6. 
 
9.3. UV Spectrometric Study of Prepared Complexes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.7: λmax of prepared complexes 
 
 
The λmax of Aceclofenac in Methanol shows 275 nm and prepared complex 
(formulation F2) shows 276 nm. This slight change is due to formation of inclusion 
complex. 
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9.4. Fourier Transform Infrared (FTIR) Spectroscopy: 
 
 
 
Fig. 9.8: FTIR spectrum of Aceclofenac 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.9: FTIR spectrum of β-cyclodextrin 
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Fig.9.10: FTIR spectrum of formulation F2 
 
 
Table 9.10: Interpretation of FTIR spectrum of Aceclofenac 
 
 
 
 
S. No. 
Wave 
number 
(cm
-1
) 
 
Functional 
group 
Peak observed (Yes/No) 
Range 
(cm
-1
) 
 
Drug 
Drug+ β- 
CD 
 
1 
 
3316.41 
N-H 
stretching 
 
3600-3300 
 
Yes 
 
Yes 
 
2 
 
3110.41 
C-H 
stretching 
Above 
3000 
 
Yes 
 
Yes 
 
3 
 
1626.63 
C=O 
stretching 
 
1760-1615 
 
Yes 
 
Yes 
 
4 
 
1386.20 
Aromatic C- 
H stretch ing  
 
1600-1300 
 
Yes 
 
Yes 
 
 
From the above Fig. 9.8 to 9.10, it can be seen that, the major functional group 
peaks like 3316.41,  3110.41,  1626.63  and 1386.20  cm-1   showing  the functional  group 
N-H stretching,  C-H stretching,  C=O stretching  and aromatic  C-H stretching  were 
observed  in  spectra  of  drug  with  β-cyclodextrin  complex  remains  unchanged  as 
compared with spectra of Aceclofenac. 
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So, from the above IR spectra can be observed  that there is no interaction 
between Aceclofenac and β-cyclodextrin. 
 
9.5. Differential Scanning Calorimetry (DSC) Analysis: 
 
 
 
 
 
Fig. 9.11: DSC thermogram of Aceclofenac 
 
 
 
 
Fig. 9.12: DSC thermogram of β-cyclodextrin 
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Fig. 9.13 DSC thermogram of formulation F2 
 
Table 9.11: Data for DSC thermogram parameters 
 
 
 
 
S.No. 
DSC 
thermogram 
sample 
Onset 
temperature 
(° C) 
Peak 
temperature 
(° C) 
Endset 
Temperature 
(° C) 
1 Aceclofenac 152.51 153.85 155.36 
 
 
 
2 
 
Aceclofenac 
 
+ β-CD 
 
 
 
151.22 
 
 
 
152.24 
 
 
 
153.47 
 
The thermal behavior of Cyclodextrin  inclusion  complex was studied using 
DSC in order to confirm the formation of inclusion complexes.  When the molecules 
are  incorporated  in  cyclodextrin  cavity  or in the  crystal  lattice,  the boiling  point, 
melting  point  and  sublimation  point  are  usually  shifted  to  different  temperature 
otherwise  disappear  within the temperature  range where the cyclodextrin  lattice is 
decomposed. 
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The DSC of pure Aceclofenac, β-Cyclodextrin and formulation F2 complexes 
are shown in Fig.9.11 – 9.13. The results of the study indicate that there are no major 
changes  between  the drug and drug carrier with reference  to the melting  point of 
Aceclofenac and β-Cyclodextrin. 
 
9.6. X-ray Diffraction Studies: 
 
 
 
 
Fig. 9.14: X-ray diffraction of pure Aceclofenac 
 
 
 
 
 
 
 
Fig. 9.15: X-ray diffraction of pure β-cyclodextrin 
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Fig. 9.16: X-ray Diffraction of formulation F2 
 
Powder X-ray diffraction study may be used to detect inclusion complexation 
in the solid state. The diffraction pattern of newly formed substances clearly differs 
from  that  of  uncomplexed   cyclodextrin.   This  difference   of  diffraction   pattern 
indicates the complex formation. 
 
The X-ray  diffraction  pattern  of pure drug shows  the peaks  that are sharp 
intense signifying its crystalline nature. Formulation F2 consists of drug and β- 
cyclodextrin  in  the  ratio  1:2  prepared  by  kneading  technique  there  is  absence  of 
intense peaks of Aceclofenac, signifying amorphous nature of complex. The results of 
the XRD pattern are shown in the Fig. 9.14-9.16. 
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9.7. Drug Content Estimation: 
 
 
Table 9.12: Drug content estimation of Aceclofenac inclusion complexes 
 
 
 
 
 
Formulation Code 
 
 
 
Percent drug content*±SD 
 
F1 
 
98.02±0.13 
 
F2 
 
99.51±0.61 
 
F3 
 
97.23±0.21 
 
F4 
 
96.21±0.58 
 
F5 
 
97.28±0.28 
 
F6 
 
95.38±0.31 
 
F7 
 
98.52±0.84 
 
F8 
 
99.01±0.21 
 
F9 
 
97.23±0.21 
 
*All the values are expressed as mean ± SD, n=3. 
 
Drug content  was found to be uniform  among  all formulations  and ranged 
from 97.23 to 99.51 %. These results showed that all formulations  having uniform 
percentage drug content as per limits given in Indian Pharmacopoeia. 
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9.8. In vitro Dissolution Studies: 
 
Table.9.13: Dissolution profile of formulation F1 
 
 
S. No. 
 
Time (min) 
 
DR* (%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
8.25±0.18 
 
8.25 
 
4.79 
 
0.50 
 
3 
 
10 
 
20.48±1.22 
 
20.48 
 
9.49 
 
0.99 
 
4 
 
15 
 
33.86±1.61 
 
33.86 
 
13.88 
 
1.43 
 
5 
 
30 
 
57.26±0.33 
 
57.26 
 
18.02 
 
1.90 
 
6 
 
45 
 
75.09±1.63 
 
75.09 
 
21.86 
 
2.28 
 
7 
 
60 
 
83.37±1.81 
 
83.37 
 
25.72 
 
2.91 
 
*All the values are expressed as mean ± SD, n=3. 
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Fig.9.17: Dissolution profile of formulation F1 
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Table 9.14: Dissolution profile of formulation F2 
 
 
S. No. 
 
Time (min) 
 
DR* (%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
26.55±0.80 
 
26.55 
 
12.07 
 
2.50 
 
3 
 
10 
 
43.33±1.05 
 
43.33 
 
23.06 
 
4.75 
 
4 
 
15 
 
55.55±1.92 
 
55.55 
 
32.14 
 
6.49 
 
5 
 
30 
 
85.18±1.20 
 
85.18 
 
51.82 
 
12.00 
 
6 
 
45 
 
93.99±0.29 
 
93.99 
 
64.75 
 
14.28 
 
7 
 
60 
 
97.54±0.89 
 
98.54 
 
73.15 
 
16.93 
*All the values are expressed as mean ± SD, n=3. 
 
 
 
 
 
 
 
 
 
100  
90  
80  
70  
60  
50  
40  
30  
20  
10  
0 
 
 
 
 
 
 
 
F2  
 
 
 
 
 
0               5              10             15             30             45             60 
 
Time in minutes  
 
 
Fig. 9.18: Dissolution profile of formulation F2 
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Table 9.15: Dissolution profile of formulation F3 
 
 
S. No. 
 
Time 
(min) 
 
DR* (%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
8.27±1.21 
 
8.27 
 
3.59 
 
2.50 
 
3 
 
10 
 
25.46±0.67 
 
25.46 
 
8.92 
 
5.82 
 
4 
 
15 
 
32.83±0.30 
 
32.83 
 
15.17 
 
8.31 
 
5 
 
30 
 
52.28±0.22 
 
52.28 
 
29.56 
 
13.53 
 
6 
 
45 
 
65.89±0.89 
 
65.89 
 
39.77 
 
18.11 
 
7 
 
60 
 
75.09±1.49 
 
75.09 
 
47.71 
 
22.56 
*All the values are expressed as mean ± SD, n=3. 
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Fig. 9.19: Dissolution profile of formulation F3 
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Table 9.16: Dissolution profile of formulation F4 
 
 
S. No. 
 
Time (min) 
 
DR* (%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
11.89±1.33 
 
11.89 
 
5.71 
 
2.50 
 
3 
 
10 
 
24.68±0.89 
 
24.68 
 
11.04 
 
4.82 
 
4 
 
15 
 
32.37±1.25 
 
32.37 
 
16.59 
 
7.69 
 
5 
 
30 
 
51.09±1.53 
 
51.09 
 
29.56 
 
12.62 
 
6 
 
45 
 
61.28±1.40 
 
61.28 
 
38.83 
 
17.58 
 
7 
 
60 
 
72.85±1.97 
 
72.85 
 
45.76 
 
20.43 
*All the values are expressed as mean ± SD, n=3. 
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Fig.9.20: Dissolution profile of formulation F4 
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Table 9.17: Dissolution profile of formulation F5 
 
 
S. No. 
 
Time (min) 
 
DR* (%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
10.45±1.17 
 
10.45 
 
5.00 
 
2.50 
 
3 
 
10 
 
20.74±1.49 
 
20.74 
 
9.63 
 
4.79 
 
4 
 
15 
 
37.74±1.65 
 
37.74 
 
15.65 
 
8.64 
 
5 
 
30 
 
53.90±0.96 
 
53.90 
 
30.15 
 
12.75 
 
6 
 
45 
 
67.73±0.77 
 
67.73 
 
39.46 
 
17.14 
 
7 
 
60 
 
80.82±0.96 
 
80.82 
 
47.65 
 
24.57 
*All the values are expressed as mean ± SD, n=3. 
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Fig.9.21: Dissolution profile of formulation F5 
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Table 9.18: Dissolution profile of formulation F6 
 
 
S. No. 
 
Time (min) 
 
DR* (%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
9.48±1.22 
 
9.48 
 
5.71 
 
2.50 
 
3 
 
10 
 
20.83±1.89 
 
20.83 
 
11.04 
 
4.82 
 
4 
 
15 
 
36.84±1.55 
 
36.84 
 
16.59 
 
7.69 
 
5 
 
30 
 
53.31±1.72 
 
53.31 
 
29.56 
 
12.62 
 
6 
 
45 
 
61.44±0.91 
 
61.44 
 
38.83 
 
17.58 
7 
 
60 
 
68.16±2.17 
 
68.16 
 
45.76 
 
20.43 
*All the values are expressed as mean ± SD, n=3. 
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Fig.9.22: Dissolution profile of formulation F6 
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Table 9.19: Dissolution profile of formulation F7 
 
 
S. No.  
Time (min) 
 
DR* 
(%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
10.38±0.44 
 
10.38 
 
5.00 
 
2.50 
 
3 
 
10 
 
26.59±0.89 
 
26.59 
 
10.69 
 
5.30 
 
4 
 
15 
 
36.85±1.41 
 
36.85 
 
16.82 
 
7.88 
 
5 
 
30 
 
56.59±1.57 
 
56.59 
 
31.44 
 
13.35 
 
6 
 
45 
 
68.38±1.26 
 
68.38 
 
41.97 
 
17.78 
 
7 
 
60 
 
77.47±0.80 
 
77.47 
 
49.89 
 
21.56 
*All the values are expressed as mean ± SD, n=3. 
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Fig.9.23: Dissolution profile of formulation F7 
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Table 9.20: Dissolution profile of formulation F8 
 
 
S. No. 
 
Time (min) 
 
DR* 
(%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
11.63±0.96 
 
11.63 
 
5.71 
 
2.50 
 
3 
 
10 
 
24.79±0.89 
 
24.79 
 
11.39 
 
4.99 
 
4 
 
15 
 
37.49±1.19 
 
37.49 
 
17.53 
 
7.87 
 
5 
 
30 
 
55.27±0.89 
 
55.27 
 
32.50 
 
13.21 
 
6 
 
45 
 
70.71±1.06 
 
70.71 
 
42.68 
 
16.75 
 
7 
 
60 
 
83.68±0.86 
 
83.68 
 
50.95 
 
23.40 
 
*All the values are expressed as mean ± SD, n=3. 
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Fig.9.24: Dissolution profile of formulation F8 
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Table 9.21: Dissolution profile of formulation F9 
 
 
S. No. 
 
Time (min) 
 
DR* 
(%) 
 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 
 
0 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
2 
 
5 
 
7.74±1.33 
 
7.74 
 
2.88 
 
2.50 
 
3 
 
10 
 
19.82±1.20 
 
19.82 
 
7.15 
 
5.81 
 
4 
 
15 
 
31.18±0.96 
 
31.18 
 
12.82 
 
8.84 
 
5 
 
30 
 
48.63±1.17 
 
48.63 
 
26.26 
 
13.65 
 
6 
 
45 
 
63.52±1.65 
 
63.52 
 
36.39 
 
19.86 
 
7 
 
60 
 
73.31±1.79 
 
73.31 
 
44.82 
 
24.17 
 
*All the values are expressed as mean ± SD, n=3. 
 
 
 
 
 
 
Fig.9.25: Dissolution profile of formulation F9 
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Fig.9.26: Dissolution profile of inclusion complex (kneading method) 
containing various ratio i.e. 1:1, 1:2, 1:3 
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Fig.9.27: Dissolution profile of inclusion complex (common solvent method) 
containing various ratio i.e. 1:1, 1:2, 1:3 
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Fig.9.28: Dissolution profile of inclusion complex (physical mixture) 
containing various ratio i.e. 1:1, 1:2, 1:3 
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Table 9.22: Comparative dissolution profile of all formulations 
 
 
 
Time 
in 
(min) 
 
 
Percentage drug release (%) 
 
 
F1 
 
 
F2 
 
 
F3 
 
 
F4 
 
 
F5 
 
 
F6 
 
 
F7 
 
 
F8 
 
 
F9 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
5 
8.25± 
0.81 
26.55± 
0.80 
8.27± 
1.21 
11.89± 
1.33 
10.45± 
1.17 
9.48±1. 
22 
10.38± 
0.44 
11.63± 
0.96 
7.74± 
1.33 
 
10 
20.48± 
1.22 
43.33± 
1.05 
25.46± 
0.67 
24.68± 
0.89 
20.74± 
1.49 
20.83± 
1.89 
26.59± 
0.89 
24.79± 
0.89 
19.82 
±1.20 
 
15 
33.86± 
1.61 
55.55± 
1.92 
32.83± 
0.30 
32.37± 
1.25 
37.74± 
1.65 
36.84± 
1.55 
36.85± 
1.49 
37.49± 
1.19 
31.18 
±0.96 
 
30 
57.26± 
0.33 
85.18± 
1.20 
52.28± 
0.22 
51.09± 
1.53 
53.90± 
0.96 
53.31± 
1.72 
56.59± 
1.57 
55.27± 
0.89 
48.63 
±1.17 
 
45 
75.09± 
1.63 
93.99± 
0.29 
65.89± 
0.89 
61.28± 
1.40 
67.73± 
0.77 
61.44± 
0.91 
68.38± 
1.26 
70.71± 
1.06 
63.52 
±1.64 
 
60 
83.37± 
1.81 
97.54± 
0.89 
75.09± 
1.49 
72.85± 
1.97 
80.82± 
0.96 
68.16± 
2.17 
77.47± 
0.80 
83.68± 
0.86 
73.31 
±1.79 
 
 
*All the values are expressed as mean ± SD, n=3. 
 
 
 
 
 
 
Fig.9.29: Comparative dissolution profile of all formulations 
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Fig.9.29: Comparative dissolution profile of all formulations 
 
 
 
 
Fig. 9.30: Comparative dissolution profile of drug content, marketed 
formulation and formulation F2 
 
The  dissolution   studies  revealed   that  all  the  formulations   showed  and 
increased  rate  the  complex  prepared  by  kneading  method  was  found  to  yield  a 
complex  of higher  rate of dissolution  over common  solvent  and physical  mixture 
method. The results of the dissolution study indicates that formulation F2 prepared by 
kneading method released to the maximum amount of drug and gave maximum 
percentage of drug release was above 97.54 %±0.89 within hour when compared to 
all other formulations. 
The dissolution study of all the formulations was showed in Table 9.17-9.21 
and Fig. 9.17-9.25. 
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9.9. Stability Studies: 
 
After storage the formulation F2 was analyzed for various parameters, results 
are showed in Table 9.23. 
Table 9.23: Stability study of formulation F2 of inclusion complex Aceclofenac  at 
room temperature 25° C ± 2° C / 60 % RH ± 5 % and accelerated temperature 40°  C 
± 2° C / 75 % RH ± 5 %. 
 
 
 
 
 
Parameter 
 
 
 
 
Initial 
At 25° C ± 2° C / 60 % 
RH±5 % 
At 40° C ± 2° C / 75 % 
RH ± 5 %. 
1
st
 
 
Month 
2
nd
 
 
Month 
3
rd
 
 
Month 
1
st
 
 
Month 
2
nd
 
 
Month 
3
rd
 
 
Month 
Drug 
content 
(%) 
 
99.69± 
 
1.20 
 
99.31± 
 
1.54 
 
99.20± 
 
0.32 
 
99.06± 
 
0.28 
 
99.54± 
 
0.52 
 
99.17± 
 
0.35 
 
99.02± 
 
0.41 
In vitro 
drug 
release at 
end of 60 
minute. 
 
 
 
 
97.54± 
 
0.89 
 
 
 
 
97.39± 
 
0.19 
 
 
 
 
97.07± 
 
0.98 
 
 
 
 
96.81± 
 
0.68 
 
 
 
 
96.62± 
 
1.11 
 
 
 
 
96.35± 
 
0.32 
 
 
 
 
96.11± 
 
1.01 
 
*All the values are expressed as mean ± SE, n=3. 
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Fig.9.31: Comparisons of drug content before and after stability period at room 
temperature (25° C ± 2° C / 60 % RH ± 5 %) 
 
 
Fig.9.32: Comparisons of in vitro cumulative % drug release before and after stability 
period at room temperature (25° C ± 2° C / 60 % RH ± 5 %) 
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Fig.9.33: Comparisons of drug content before and after stability period at accelerated 
temperature (40° C ± 2° C / 75 % RH ± 5 %) 
 
 
 
 
Fig.9.34:  Comparisons of in vitro cumulative % drug release before and after 
stability period at accelerated temperature (40° C ± 2° C / 75 % RH ± 5 %) 
Inclusion Complexes of Aceclofenac Results and Discussion  
Adhiparasakthi college of pharmacy, Melmaruvathur. Page 95 
 
 
 
 
 
Fig.9.35: Comparisons of drug content before and after stability period at room 
temperature and accelerated temperature 
 
 
 
 
Fig.9.36: Comparisons of in vitro cumulative % drug release before and after stability 
period at room temperature and accelerated temperature 
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The  complex  prepared  by  kneading   method  in  the  molar  ratio  of  1:2 
(formulation  F2)  was  found  to  exhibit  a  better  stability  under  certain  storage 
condition. 
 
There were no major differences between the evaluated parameters like drug 
content, in vitro dissolutions and all the results were acceptable limits. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
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CONCLUSION 
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10. SUMMARY AND CONCLUSION 
 
 
 
 
 
Among  the emerging  new chemical  entities,  most are poorly water soluble 
drugs  putting  impact  on their bioavailability  and therapeutic  effect.  The solubility 
enhancement   techniques   also  play   an  important   role  in  getting   the  excellent 
dissolution  properties  of poorly soluble drugs. Successful  improvement  in aqueous 
solubility is mainly depends on the method which we choose. Inclusion complex with 
β-cyclodextrins  is  the  most  attractive  technique  to  enhance  aqueous  solubility  of 
poorly soluble drugs. β-cyclodextrins, act as the useful solubilizer enabling both 
solid/liquid  oral and parenteral  dosage  forms.  Solid binary  system of drug and β- 
cyclodextrins are capable to modify the physicochemical properties of drugs such as 
solubility, particle size, crystal habit, thermal behavior, and there by forming a highly 
water  soluble  amorphous  forms.  The  β-cyclodextrins,  due  to  their  extreme  high 
aqueous solubility, they became capable to enhance the dissolution rate and bio- 
availability of the poorly soluble drugs. The permeation of insoluble drugs through 
various   biological   membranes   can   also   be   enhanced   by   preparing   drug-   β- 
cyclodextrins inclusion compounds. 
The present study was aimed to improving the dissolution of poorly soluble 
drug Aceclofenac, being a drug acidic in nature shows a poor solubility in biological 
fluids. Hence, an attempt was made to prepare β-cyclodextrins inclusion complex of 
Aceclofenac by different techniques. 
Literature survey revealed that cyclodextrin has been extensively study to 
improve solubility, dissolution rate of various drugs. Due to its less price and easy 
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availability,  β-cyclodextrin   is  widely  used.  It  is  a  less  toxic  among  all  other 
derivatives of cyclodextrins.  
The preliminary work was studied by performing preformulation studies. The 
identification drugs was determined by conducting the experiment on melting point, 
solubility,  loss  on  drying,  FTIR  and  assay.  The  data  obtained  from  these  studies 
indicated that the drugs are confirmed as Aceclofenac. 
β-cyclodextrin inclusion complex were prepared by different methods like 
kneading, common solvent and physical mixture in the ratio of 1:1, 1:2 and 1:3. 
The prepared inclusion complex characterised by various analytical techniques 
like UV spectrophotometer, Fourier Transform Infrared Spectroscopy, Differential 
Scanning Calorimetry and X-ray diffraction studies.  
The phase solubility studies were carried out according to the method Higuchi 
and Connors. It revealed that the solubility of Aceclofenac increased linearly with the 
increase in concentration of β-cyclodextrin. 
The UV spectra of Aceclofenac and inclusion complex in the Methanol were 
studied to know maximum absorbance (λmax). There was no shift in the λmax of 
Aceclofenac in the presence of β-cyclodextrin. 
Fourier  Transform  Infrared  Spectroscopy  and  Differential  Scanning 
Calorimetry indicated the formation of true inclusion complexes of Aceclofenac with 
β-cyclodextrin in 1:2 ratio prepared by kneading method. 
The X-ray  diffraction  pattern  confirmed  the formation  of complex  with β- 
cyclodextrin and the substance exhibits amorphous form. 
The drug content of formulation F2 was found to be official limit.  
Inclusion Complexes of Aceclofenac Summary and Conclusion  
Adhiparasakthi college of pharmacy, Melmaruvathur. Page 99 
 
 
From  the  dissolution  profiles  of  inclusion  complex  prepared  by  kneading 
method  concludes  that β-cyclodextrin  is more  meaningful  for the enhancement  of 
solubility and dissolution rate of Aceclofenac. 
The inclusion complex prepared by kneading method revealed that more stable 
in the molar ratio of 1:2 at the end of three months. 
So, it can be concluded that inclusion complex of Aceclofenac with β- 
cyclodextrin could be prepared successfully by kneading method in a molar ratio of 
1:2. 
 
It can be concluded that an inclusion complex of Aceclofenac with β- 
cyclodextrin could be prepared successfully by kneading in a molar ratio of 1:2 and 
this was confirmed by phase solubility studies, UV spectrophotometry, Fourier 
Transform  Infrared  Spectroscopy,  Differential  Scanning  Calorimetry,  X-ray 
diffraction, drug content estimation, in vitro dissolution study and stability studies. 
From the overall studies formulation F2 considered as best formulation. 
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11. FUTURE PROSPECTUS 
 
 
 
 
In  the  present  work  summarized  and  concluded  the  β-cyclodextrin  inclusion 
complex  of Aceclofenac  were  prepared  successfully  by  kneading  method  and  it was 
characterised by various analytical techniques. In the present investigation in vitro 
characterisation was performed. Along with this study there is need of In vivo studies to 
set up the in vitro – in vivo correlation  for the better efficacy  of Aceclofenac  in the 
treatment of rheumatoid arthritis with reducing gastrointestinal side effects. 
Long term stability to be performed in future as per the ICH guidelines. 
 
The   best   inclusion   complex   of   Aceclofenac   was   chosen   in   future   for 
manufacturing of tablet formulation and evaluated for in vitro and in vivo performance. 
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